A Pilot (Phase 1) Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade (Ipilimumab and Nivolumab) Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma
Phase: PHASE1
Conditions: Melanoma
Sponsor: Ludwig Institute for Cancer Research

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 1 of 70 
 
Study Protocol 
LUD2015-006 
US-IND# exempt 
BMS CA209-412 
Amendment 5 
FINAL 
12-JUN-2018 
 
Protocol Title 
A Pilot (Phase 1) Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade 
(Ipilimumab and Nivolumab) Plus External Beam Radiotherapy in Subjects with Stage IV 
Melanoma 
 
Objectives and Synopsis 
This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and 
nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. 
All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 
doses, followed by nivolumab monotherapy (240 mg every 2 weeks). Note: per Amendment 5, 
nivolumab monotherapy continuing after Week 18 may be given as 480 mg every 4 weeks.  
Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy. 
There will be 2 cohorts in the study. Subjects in Cohort A will initially receive a conventional total 
palliative dose of 30 Gy delivered over 2 weeks in 10 fractions of 3 Gy each. Once 9 subjects have been 
accrued to Cohort A and completed the concurrent ipilimumab and nivolumab therapy, if ≤ 7 subjects 
have Grade 3 or 4 drug- or radiation-related adverse events, the safety of Cohort A will be deemed 
acceptable and additional subjects will be accrued to Cohort B (see exception in Section 3.1, i.e., 
asymptomatic amylase and lipase abnormalities are not included). Subjects in Cohort B will receive the 
high-dose hypofractionated RT for which treatment of a target lesion will comprise a total palliative 
dose of 27 Gy delivered over 2 weeks in 3 fractions of 9 Gy each. 
The primary objective is the assessment of safety according to the National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. 
The secondary objectives are to evaluate: (1) objective response rate (ORR) at Weeks 12 and 18, (2) 
disease control rate (DCR) at Weeks 12 and 18, (3) duration of response, (4) progression-free survival 
(PFS), and (5) overall survival (OS). 
The exploratory objectives are to perform correlative studies investigating the immunological effects of 
ipilimumab and nivolumab with RT. 
Assessment methods include the NCI CTCAE (Version 4.03) for safety and the modified Response 
Evaluation Criteria for Solid Tumors (RECIST) 1.1 (primary) and immune-related RECIST (irRECIST; 
secondary) for clinical efficacy. 
 
Sponsor:  Ludwig Institute for Cancer Research,  
New York, NY 
 
 
 
 
 
 
Sponsor representative Signature & Date 
Study Chair:  Michael Postow, MD, Memorial Sloan 
Kettering Cancer Center (MSKCC) 
 
 
 
 
 
 
Study Chair Signature & Date 
 
Confidentiality Statement 
The confidential and proprietary information in this document is owned by the Ludwig Institute for Cancer Research and 
provided to you as an Investigator, potential Investigator, or consultant, for review by you, your staff, and applicable institutional 
review board(s). The information cannot be used, or divulged to any third party or published without the written consent of the 
Ludwig Institute for Cancer Research, except to the extent necessary to obtain informed consent from those persons to whom 
study medication may be administered. Any misappropriation of this information is prohibited by law. 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 2 of 70 
Table of Contents 
1 
Background ............................................................................................................................. 5 
1.1 
Melanoma ....................................................................................................................... 5 
1.2 
Ipilimumab ....................................................................................................................... 5 
1.3 
Nivolumab ....................................................................................................................... 6 
1.4 
Radiotherapy for Melanoma ........................................................................................... 6 
2 
Study Rationale ....................................................................................................................... 8 
2.1 
Preclinical Rationale for Combining Radiotherapy and Checkpoint Blockade ................ 8 
2.2 
Clinical Rationale for Combining Radiotherapy and Checkpoint Blockade ..................... 9 
3 
Experimental Plan ................................................................................................................. 10 
3.1 
Study Design .................................................................................................................. 10 
3.1.1 
Study Phase ........................................................................................................... 10 
3.1.2 
Enrollment/Randomization ................................................................................... 10 
3.1.3 
Blinding/Unblinding ............................................................................................... 10 
3.1.4 
Subject Population................................................................................................. 11 
3.1.5 
Number of Sites/Subjects ...................................................................................... 11 
3.1.6 
Sample Size and Statistical Considerations ........................................................... 11 
3.1.7 
Treatment Arms and Treatment Schema .............................................................. 11 
3.1.8 
Dosing Adjustments, Delays, and Discontinuations .............................................. 12 
3.1.9 
Dose-limiting Toxicity ............................................................................................ 12 
3.1.10 
Subject Withdrawal from Treatment or from Study ............................................. 12 
3.1.11 
Subject Evaluability and Subject Replacement ..................................................... 13 
3.1.12 
Optional Study Treatment Extension .................................................................... 13 
3.1.13 
Interim Analysis ..................................................................................................... 13 
3.1.14 
Safety Monitoring and Study Stopping Rules ........................................................ 13 
3.1.15 
Duration of Study .................................................................................................. 14 
3.1.16 
On Study and Post-Study Follow-up ...................................................................... 14 
3.2 
Study Flowchart ............................................................................................................. 15 
4 
Study Objectives & Endpoints .............................................................................................. 18 
4.1 
Safety and Tolerability ................................................................................................... 18 
4.1.1 
Endpoints & Assessment Methods ........................................................................ 18 
4.1.2 
Subject Evaluation & Statistics .............................................................................. 18 
4.2 
Clinical Efficacy .............................................................................................................. 19 
4.2.1 
Endpoints & Assessment Methods ........................................................................ 19 
4.2.1.1 
Tumor Response and Overall Response Rate ................................................ 19 
4.2.1.2 
Disease Control Rate ..................................................................................... 19 
4.2.1.3 
Duration of Response .................................................................................... 19 
4.2.1.4 
Progression-free Survival ............................................................................... 20 
4.2.1.5 
Overall Survival .............................................................................................. 20 
4.2.2 
Subject Evaluation & Statistics .............................................................................. 20 
4.3 
Antitumor Immunity ...................................................................................................... 20 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 3 of 70 
4.3.1 
Endpoints & Assessment Methods ........................................................................ 20 
4.4 
Additional Exploration of Immune Response ................................................................ 21 
5 
Subject Eligibility ................................................................................................................... 22 
5.1 
Inclusion Criteria ............................................................................................................ 22 
5.2 
Exclusion Criteria ........................................................................................................... 23 
5.3 
Restrictions on Concomitant Therapies ........................................................................ 25 
5.3.1 
Non-Permitted Concomitant Therapies ................................................................ 25 
5.3.2 
Permitted Concomitant Therapies ........................................................................ 25 
6 
Study Drug Preparation and Administration ........................................................................ 26 
6.1 
Ipilimumab and Nivolumab ........................................................................................... 26 
6.1.1 
Nivolumab Storage Conditions & Handling ........................................................... 26 
6.1.2 
Nivolumab Preparation and Administration ......................................................... 27 
6.1.3 
Ipilimumab Storage Conditions & Handling .......................................................... 28 
6.1.4 
Ipilimumab Preparation and Administration ......................................................... 28 
6.2 
Radiotherapy ................................................................................................................. 29 
6.3 
Drug Overdose Management ........................................................................................ 29 
7 
Administrative, Legal & Ethical Requirements ..................................................................... 30 
7.1 
Documentation and Reporting of Adverse Events ........................................................ 30 
7.1.1 
General AE/SAE Definitions per ICH Guidelines .................................................... 30 
7.1.2 
Additional SAE Definitions for this Study .............................................................. 31 
7.1.3 
Severity of an Adverse Event ................................................................................. 31 
7.1.4 
Relationship of Adverse Events to Study Drug ...................................................... 31 
7.1.5 
General Reporting Requirements .......................................................................... 32 
7.1.6 
Expedited Serious Adverse Event (SAE) Reporting Requirements ........................ 32 
7.1.7 
Serious Adverse Event (SAE) Follow-up Requirements ......................................... 33 
7.2 
Administrative Sponsor Requirements ......................................................................... 33 
7.2.1 
Study Master Files ................................................................................................. 33 
7.2.2 
Case Report Form Data Collection ........................................................................ 33 
7.2.3 
Language ................................................................................................................ 33 
7.2.4 
Monitoring ............................................................................................................. 34 
7.2.5 
Protocol Amendments ........................................................................................... 34 
7.2.6 
Premature Subject Withdrawal ............................................................................. 34 
7.2.7 
Early Trial Termination .......................................................................................... 34 
7.2.8 
Study Drug Shipments & Accountability ............................................................... 35 
7.3 
Regulatory, Legal, & Ethical Requirements ................................................................... 36 
7.3.1 
Good Clinical Practice (GCP), Laws and Regulations ............................................. 36 
7.3.2 
Informed Consent .................................................................................................. 36 
7.3.3 
Institutional Review Board .................................................................................... 36 
7.3.4 
Subject Confidentiality .......................................................................................... 36 
8 
Appendices ........................................................................................................................... 38 
8.1 
Protocol Version History ................................................................................................ 38 
8.2 
Participating Study Sites, Investigators and Staff, Laboratories, and Sponsor 
Information ............................................................................................................................... 45 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 4 of 70 
8.3 
Ipilimumab and Nivolumab Dose Delays and Adjustments .......................................... 46 
8.3.1 
Management Algorithms for Adverse Events Associated with Immuno-oncology 
Agents 
 ............................................................................................................................... 49 
8.4 
RECIST 1.1 and irRECIST Guidelines ............................................................................... 50 
8.5 
Recommended Guidelines for Radiation Therapy ........................................................ 58 
8.5.1 
Target selection for radiation therapy .................................................................. 58 
8.5.2 
Treatment position, immobilization, and simulation ............................................ 58 
8.5.3 
Target delineation ................................................................................................. 59 
8.5.4 
Organ at risk dose (OAR) delineation and dose constraints.................................. 60 
8.5.5 
Beam selection and geometry, planning technique and treatment delivery ....... 63 
8.5.6 
Radiotherapy timing and dose fractionation ........................................................ 63 
8.6 
Exploratory Assessment of Correlative Immunologic Research .................................... 64 
8.7 
Abbreviations................................................................................................................. 65 
9 
References ............................................................................................................................ 67 
 
LIST OF TABLES 
Table 1. 
Treatment Schema .................................................................................................... 11 
 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 5 of 70 
1 Background 
1.1 Melanoma 
The incidence of malignant melanoma is rising and the mortality rate is increasing.(1) These 
concerning trends are occurring despite the recent decline in the incidence of several other 
cancer types. Despite this concerning trend, the overall survival (OS) for all patients diagnosed 
with melanoma has improved for early stage tumors because of early detection and improved 
surgical treatment. Nonetheless, many patients who undergo curative-intent surgical treatment 
of high-risk disease ultimately recur, and recurrent and/or metastatic melanoma remains a 
largely fatal disease, with a median survival of 3 to 11 months.(2) 
The only adjuvant treatment approved by the US FDA after resection of high-risk melanoma is 
IFN-α. Unfortunately, treatment with high-dose IFN-α is associated with significant side effects, 
and its role in prolonging survival is not clear. One study showed an OS benefit, but this was not 
confirmed in a pooled analysis with longer follow-up.(3, 4) 
Until 2011, dacarbazine and interleukin-2 (IL-2) were the only US FDA approved treatments for 
metastatic melanoma. Dacarbazine provides an objective tumor response in only 5% to 20% of 
subjects, and these responses are short-lived (median duration of response is 6 months). 
Dacarbazine has also never been shown to improve OS.(2)  IL-2 was approved by the FDA in 
1998 for treatment of metastatic melanoma. The FDA approval was based on data suggesting a 
16% overall objective response rate with a 6% complete response. However, toxicities of high 
dose IL-2 therapy were severe (e.g., capillary leak, sepsis, and hypotension), and 2% of subjects 
died from such associated adverse events (AEs).(5)  
Since 2011, many new treatments have been approved for patients with melanoma.  For 
patients with BRAF mutations, the BRAF inhibitors dabrafenib and vemurafenib have led to 
dramatic results with recent demonstration of an overall survival benefit of combining the BRAF 
inhibitor, dabrafenib with the MEK inhibitor, trametinib.(6)  Immunotherapy with immune 
checkpoint blocking antibodies has similarly led to remarkable advances in advanced melanoma 
with 3 currently FDA-approved drugs: Ipilimumab, nivolumab, and pembrolizumab.(7-9) 
1.2 Ipilimumab 
Ipilimumab enhances antitumor immunity by blocking the normally negative regulator of T cell 
function, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and has demonstrated a survival benefit for 
subjects with advanced melanoma in two Phase 3 trials.(10, 11)  Though ipilimumab can result 
in impressive long-term tumor control,(12) unfortunately only a subset of patients benefit. 
Responses to ipilimumab are often delayed and may be seen after initial apparent disease 
progression. The unique pattern of disease response seen in subjects with ipilimumab led to a 
retrospective study analyzing subjects treated across several Phase 2 trials.(13)  In this 
evaluation, improved survival was associated with a variety of disease response patterns such as 
subjects who initially appeared to have progressive disease but later achieved response and 
those who had prolonged stable disease.  
Though ipilimumab is generally well tolerated, a unique set of side effects, termed immune-
related adverse events (irAEs) has been seen during its clinical development. The most severe 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 6 of 70 
irAE is generally considered to be an inflammatory enterocolitis which requires prompt 
treatment with steroids and, in some cases, anti-TNF-alpha therapy. Unfortunately, a 
randomized trial evaluating the role of prophylactic budesonide in decreasing the rate of 
inflammatory colitis showed no benefit to this approach.(14)  Other common severe side effects 
related to ipilimumab include hepatitis, dermatitis (including toxic epidermal necrolysis), 
neuropathy, and endocrinopathy. The following clinically significant immune-mediated adverse 
reactions were seen in less than 1% of ipilimumab-treated subjects in one study: nephritis, 
pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.(7)  
1.3 Nivolumab 
Nivolumab enhances antitumor immunity by blocking another negative regulator of immunity, 
programmed cell death-1 (PD-1) and has demonstrated high response rates in a number of 
malignancies and improved OS in subjects with melanoma.(15-17)  Since both ipilimumab and 
nivolumab act upon distinct components of the immune system, several studies are now 
investigating the combination of both ipilimumab and nivolumab. Impressive early efficacy was 
seen with an acceptable safety profile in one Phase 1 study.(18)  Impressive efficacy has also 
been seen in phase 2 and 3 trials where the combination of nivolumab and ipilimumab was 
shown to improve response rates and progression free survival compared to ipilimumab 
alone.(19, 20) 
1.4 Radiotherapy for Melanoma 
Radiotherapy (RT) is commonly used to palliate symptoms arising from sites of metastatic 
melanoma.(21)  In one study, 9 of 23 subjects who received RT achieved a complete response in 
the irradiated area, including 3 of 23 subjects who were rendered free of disease for at least 
56 months after RT.(22)  RT for melanoma has also been shown to improve symptoms and 
prevent impending complications from metastatic disease. One prospective study evaluated 
palliative endpoints for 90 subjects with renal cell carcinoma and melanoma who underwent 
palliative RT. Improvements in two-thirds of the painful bone or soft tissue lesions were noted 
by investigators.(23)  
The most effective dose and schedule of RT for subjects with metastatic melanoma, however, is 
not completely clear. In a study conducted by Overgaard et al., there was no difference in 
response rate between subjects receiving 5 Gy per fraction for 8 fractions versus 9 Gy per 
fraction for 3 fractions, though subject numbers were small.(24)  In another study, Sause et al. 
reported the results of the Radiation Therapy Oncology Group trial 83-05, which assigned 137 
subjects with melanoma to 8 Gy per fraction delivered once weekly for 4 fractions or 2.5 Gy per 
fraction delivered 5 days per week for 20 total fractions.(25)  The response rates for both 
treatment arms were not statistically significantly different. These results differed slightly from a 
retrospective analysis of 84 subjects conducted at the Mayo Clinic, which indicated that higher 
doses of RT were associated with improved palliation and improved survival.(26)  Importantly, 
dose per fraction and location of the irradiated lesions did not appear to correlate with the 
effectiveness of RT in this study. 
It is generally believed that high-dose palliative RT is feasible for subjects with metastatic 
melanoma,(24) but no rigorous evaluation of dosing schemes has been tested in large, 
randomized studies. The dose and fractionation may have immunologic implications. Schaue et 
al. found that immunologic effects and tumor control in a B16 murine melanoma model 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 7 of 70 
depended upon dose and schedule of RT.(27)  Tumor control was most effective and 
immunologic effects were most profound when RT was delivered via 7.5 Gy per fraction. In 
another study, when RT was delivered with anti-CTLA4 therapy, synergy was not seen when a 
single fraction of 20 Gy of RT was delivered.(28)  A third preclinical study showed that 
conventionally fractionated RT abrogated the immunologic effects of RT.(29)  Many radiation 
oncologists feel that a higher dose per fraction approach may be preferable, though prospective 
clinical evaluation of dose and schedule of RT in subjects with metastatic melanoma is 
necessary. 
 
 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 8 of 70 
2 Study Rationale 
2.1 Preclinical Rationale for Combining Radiotherapy and Checkpoint 
Blockade 
To increase the numbers of subjects who benefit from ipilimumab and nivolumab, clinical trials 
have started combining checkpoint antibodies with other therapeutic modalities, such as 
chemotherapy, targeted therapy, and other immunotherapy. One additional, similarly promising 
approach involves combining checkpoint antibodies with RT. In a Phase 1/2 study in metastatic 
castration-resistant prostate cancer, ipilimumab in combination with RT demonstrated clinical 
antitumor activity and manageable AEs.(30)  Other clinical trials exploring RT and checkpoint 
antibodies are ongoing.  
Conceptually, all of these additional therapeutic modalities, including localized RT, could result 
in increased tumor destruction, releasing tumor antigens that provide further stimulus to T cells 
disinhibited by checkpoint blockade therapy to enhance durable antitumor immunity. It is also 
possible that RT may alter the tumor microenvironment and render the tumor cells more 
susceptible to immunologic-mediated disease regression.  
In preclinical models, RT has been shown to enhance antitumor immune responses through 
multiple mechanisms, including increased antigen presentation in tumor draining lymph nodes 
and enhanced effector cell migration to the irradiated tumor.(29, 31)  In one study, tumors that 
received RT had improved localization of inflammatory cells into the tumor microenvironment 
following adoptive cell transfer, which was associated with upregulation of vascular cell 
adhesion molecules in the tumor microvasculature that may have played a mechanistic role. RT 
has also been shown to increase MHC-I expression and increase the efficacy of adoptive cell 
transfer.(32) 
In addition to RT’s direct immunologic effects, preclinical evaluation has demonstrated synergy 
with other immunotherapeutic approaches. Specifically, when RT was combined with the 
immunostimulatory cytokine, FMS-like tyrosine kinase 3 (Flt3), in a lung cancer model, only mice 
who received RT with Flt3 had improved survival.(33)  This survival was associated with the 
reduced development of distant pulmonary metastatic disease. A functional immune system 
appeared to be important as the effect was not seen in mice with deficient T cells. Regression of 
tumors outside of the irradiated field was also seen when Flt3 was combined with RT in a 
murine breast cancer model but not in mice treated with either modality alone.(34) 
The immunologic effects of RT may be further enhanced by concomitant anti-CTLA-4 or anti-PD-
1/PD-L1 therapy. In mouse models, CTLA-4 blockade alone resulted in no significant tumor 
growth inhibition, but when localized RT was administered in combination with CTLA-4 
blockade, antitumor effects were seen outside of the irradiated field—a phenomenon known as 
the abscopal effect.(28, 35)  Though the precise mechanisms involved in the abscopal effect are 
not completely clear, T cells appear to play a central role.(34)  This phenomenon has been 
replicated in multiple solid tumor murine models (Susan Knox, personal communication). RT and 
PD-1/PD-L1 blockade have also demonstrated synergy in preclinical models.(36, 37)  The triple 
combination of CTLA-4, PD-1, and RT has also been explored in preclinical models and suggests 
even greater efficacy when all three modalities are combined.(38) 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 9 of 70 
2.2 Clinical Rationale for Combining Radiotherapy and Checkpoint 
Blockade 
To evaluate the potential synergy between RT and immunomodulatory therapy, Formenti et al. 
conducted a proof of concept study for subjects with multiple solid tumors combining RT and 
granulocyte-macrophage colony stimulating factor (GM-CSF). They reported that 4 of the 12 
evaluable subjects (30%) experienced an abscopal response, defined as a partial response of at 
least 1 lesion outside of the treatment field.(39)  Though subject numbers were low, recent data 
have additionally shown an unusually high systemic response rate when RT was combined with 
IL-2 therapy.(40)  
Other case reports have suggested synergy between radiotherapy and immunotherapy.(41-44)  
Retrospective analysis of subjects treated with palliative RT during their induction course of 
ipilimumab at 3 mg/kg indicates that combination treatment is not associated with a higher rate 
of irAEs. Only one subject experienced a grade ≥ 3 event (diarrhea), which resolved after 
infliximab therapy. This side effect could have been related to ipilimumab alone.(45) 
Whether the dose or schedule of RT in combination with immunotherapy is relevant remains 
unknown.  Relatively low doses of conventionally fractionated RT (e.g., 30 Gy in 10 fractions) 
have been shown to be effective palliative therapy for melanoma.(23)  Higher doses of 
hypofractionated RT (e.g., 24 Gy in 3 fractions) are also frequently used in melanoma because of 
perceived “radio-resistance” due to high levels of sublethal DNA damage repair in melanoma 
cell lines, although prospective randomized clinical studies have never confirmed this.(24)  
However, the dose and fractionation of RT may have immunologic considerations relevant for its 
combination with immunotherapy.  Preclinical studies of CTLA-4 blockade combined with RT 
have demonstrated the greatest delay in tumor regrowth and highest rates of complete tumor 
response with a dose of 24 Gy in 3 fractions (versus 20 Gy in 1 fraction or 30 Gy in 5 
fractions).(28)  Another study analyzing the effect of single doses of radiation from 5-15 Gy 
found that radiation doses of 7.5 Gy yielded the greatest proportion of tumor-reactive T cells to 
regulatory T cells.(27)  Most importantly, these findings are consistent with our anecdotal 
clinical observations of abscopal effects in patients undergoing RT (both patients were treated 
with approximately 27 Gy in 3 fractions) during ipilimumab immunotherapy.   
Additional study of the relationship between RT dose and fractionation is warranted, particularly 
when considering the best strategy to combine with nivolumab and ipilimumab for patients with 
melanoma.  This information would be beneficial for subsequent studies involving combinations 
of nivolumab and ipilimumab in a variety of diseases and therapeutic settings. 
This proposed study is therefore based upon the preclinical evidence suggesting synergy 
between RT and immunomodulatory therapy and early promising clinical experiences.  The 
current study is designed to be the first prospective evaluation of the combination of 
ipilimumab, nivolumab, and RT.  

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 10 of 70 
3 Experimental Plan 
3.1 Study Design 
This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab 
and nivolumab in combination with RT in 18 subjects with unresectable Stage IV melanoma. All 
subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks 
for 4 doses (Weeks 1 through 10), followed by nivolumab monotherapy (240 mg every 2 weeks) 
through Week 18, with optional extended treatment with nivolumab as described in Section 
3.1.12. (Note: per Amendment 5, nivolumab monotherapy continuing after Week 18 may be 
given as 480 mg every 4 weeks, starting on Week 20, followed by Weeks 24, 28, etc.).  
Radiotherapy will be initiated after the first dose and before the second dose of 
immunotherapy. 
There will be 2 cohorts in the study:  
Cohort A:  
Subjects in Cohort A will initially receive a conventional total RT palliative dose of 30 Gy 
delivered over 2 weeks in 10 fractions of 3 Gy each. Once 9 subjects have been accrued to 
Cohort A and completed the concurrent ipilimumab and nivolumab therapy, if ≤ 7 subjects have 
Grade 3 or 4 drug- or radiation-related AEs, as per Section 3.1.6, the safety of Cohort A will be 
deemed acceptable and additional subjects will be accrued to Cohort B. 
Note: Grade 3 or 4 amylase or lipase abnormalities that are not associated with clinical 
symptoms will not be included in the Cohort A safety assessment described above. 
Cohort B: 
Subjects in Cohort B will receive the high-dose hypofractionated RT for which treatment of a 
target lesion will comprise a total palliative dose of 27 Gy delivered over 2 weeks in 3 fractions 
of 9 Gy each. 
Radiographic imaging will be performed at Week 12 of therapy. As responses to these 
immunotherapeutic antibodies do not always occur at the first assessment time point and RT 
effects may not be apparent at the Week 12 evaluation, repeat radiographic assessment will 
take place after 6 additional weeks at Week 18. Subjects with symptomatic progression will be 
removed from the study. 
3.1.1 Study Phase 
Pilot Phase 1 
3.1.2 Enrollment/Randomization 
Subjects will be initially enrolled in Cohort A, with subsequent enrollment into Cohort B as 
outlined in Section 3.1.7. Enrollment will be under ongoing review by an internal data safety 
monitoring panel (see Section 3.1.14, Safety Monitoring and Study Stopping Rules). 
3.1.3 Blinding/Unblinding 
This will be an open-label study. 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 11 of 70 
3.1.4 Subject Population 
Subjects with unresectable, stage IV metastatic melanoma are eligible for this study, as detailed 
further in Section 5. 
3.1.5 Number of Sites/Subjects 
This study will be conducted at 3 sites in the US, with 18 subjects estimated for enrollment. 
3.1.6 Sample Size and Statistical Considerations 
This study is intended to generate descriptive safety data. Nine subjects are anticipated for each 
cohort to enable a variety of disease presentations and RT targets. 
Prior experience with nivolumab and ipilimumab administered in combination has been 
associated with a treatment-related grade 3/4 toxicity rate of 53%.(19)  A rating of Grade 3/4 
drug- or radiation-related toxicity is considered to be acceptable in Cohort A if ≤ 7 of 9 subjects 
(78%) are affected (see exception in Section 3.1, i.e., asymptomatic amylase and lipase 
abnormalities are not included). This number was selected to avoid premature closure of 
exploration of this approach. 
As this is the first prospective study of RT plus ipilimumab and nivolumab, no historical controls 
are available to anticipate the rate of toxicity of this triple combination regimen. 
3.1.7 Treatment Arms and Treatment Schema 
Table 1 presents the schedule of treatment administration. 
Table 1. 
Treatment Schema 
 
 
Checkpoint Antibodies (IV) 
 
Cohort 
N 
Week 
Ipilimumaba  
Nivolumabb 
Radiotherapy 
Cohort A 
n = 9 
1 
3 mg/kg 
1 mg/kg 
30 Gy delivered over 2 weeks 
in 10 fractions of 3 Gy each 
2 
̶ 
̶ 
4, 7, 10 
3 mg/kg 
1 mg/kg 
̶ 
12, 14, 16, 18 
̶ 
240 mg 
̶ 
20+b 
-- 
240 mg Q2W or  
480 mg Q4W 
-- 
Cohort B 
n = 9 
1 
3 mg/kg 
1 mg/kg 
27 Gy delivered over 2 weeks 
in 3 fractions of 9 Gy each 
2 
̶ 
̶ 
4, 7, 10 
3 mg/kg 
1 mg/kg 
̶ 
12, 14, 16, 18 
̶ 
240 mg 
̶ 
20+b 
-- 
240 mg Q2W or  
480 mg Q4W 
-- 
RT will be initiated after the first dose and before the second dose of immunotherapy. 
Abbreviations: Gy = Gray; kg = kilogram(s); mg = milligram(s); N = number; IV = intravenously; Q2W = every 2 weeks; 
Q4W = every 4 weeks 
a Administered once every 3 weeks for 4 doses. (3-week cycles) 
b Administered once every 3 weeks for 4 doses (at 1 mg/kg) and then 240 mg once every 2 weeks. 
Note: per Amendment 5, nivolumab monotherapy continuing after Week 18 may be given as 480 mg every 4 weeks, 
starting on Week 20, followed by Weeks 24, 28, etc. 
See Section 6.1 for order of infusion. 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 12 of 70 
3.1.8 Dosing Adjustments, Delays, and Discontinuations 
Dosing adjustment, delays, and discontinuations of RT should be managed in accordance with 
standard of care. See Section 6.2 for administration details. 
Dosing reductions in response to toxicities of ipilimumab or nivolumab are not permitted. 
Dosing delays and discontinuations of ipilimumab and nivolumab should be managed in 
accordance with Section 8.3. The following documents may also be referenced: 
• 
YERVOY® (Ipilimumab) Package Insert: http://packageinserts.bms.com/pi/pi_yervoy.pdf  
• 
YERVOY® (Ipilimumab) Immune-mediated Adverse Reaction Management Guide: 
https://www.hcp.yervoy.com/pages/rems.aspx 
• 
Opdivo® (Nivolumab) Package Insert: http://packageinserts.bms.com/pi/pi_opdivo.pdf  
• 
Management Algorithms for Adverse Events Associated with Immuno-oncology Agents 
(see Section 8.3.1). 
Note: As durable disease stabilization and/or objective tumor response may be observed after 
early progression, it is recommended that, in the absence of toxicity requiring discontinuation in 
accordance with the package insert, all 4 doses of concurrent ipilimumab and nivolumab be 
administered over the initial 12 weeks, even in the setting of apparent clinical progression, 
provided the subject’s performance status remains stable. 
Even in the event of a dose delay, disease assessments should be performed according to 
standard of care on the originally scheduled study days. 
Dose modifications for radiotherapy as a result of toxicity are allowed per the Investigator’s 
assessment. 
3.1.9 Dose-limiting Toxicity 
The DLT and MTD will not be defined or determined.  A safety review will be conducted when 9 
subjects have been accrued to Cohort A and completed the concurrent ipilimumab and 
nivolumab therapy.  If ≤ 7 subjects have Grade 3 or 4 drug- or radiation-related AEs, the safety 
of Cohort A will be deemed acceptable and additional subjects will be accrued to Cohort B.  The 
Cohort A assessment period for this evaluation will include the first 2 cycles of treatment, up to 
and including the pre-dose safety assessments scheduled for Cycle 3 (see Section 4.1.2). 
Note: Grade 3 or 4 amylase or lipase abnormalities that are not associated with clinical 
symptoms will not be included in the Cohort A safety assessment described above. 
3.1.10  Subject Withdrawal from Treatment or from Study 
A subject will be withdrawn from study treatment for any of the following reasons: 
1. Pregnancy or intent to become pregnant. 
2. Clinical, symptomatic or radiographic progression warranting alternative treatment. 
3. Significant protocol violation or noncompliance that, in the opinion of the Investigator 
or Sponsor, warrants withdrawal. 
4. Initiation of alternative anticancer therapy including another investigational agent. 
5. Development of intercurrent, non-cancer related illnesses that prevent either 
continuation of therapy or regular follow-up. 
6. Withdrawal of consent for further treatment. 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 13 of 70 
7. Best medical interest of the subject (at the discretion of the Investigator) 
8. Discontinuation criteria per Section 8.3. 
 
Subjects who are withdrawn from study treatment should undergo the planned On Study 
Follow-up through 100 days after the last study drug administration (see the Study Flowchart in 
Section 3.2) and enter the Post Study Follow-up phase (see Section 3.1.16). 
A subject will be withdrawn from the study for the following reasons: 
 
1. Best medical interest of the subject (at the discretion of the Investigator) 
2. Withdrawal of consent for all follow-up. 
3. Lost to follow-up 
4. Death 
3.1.11 Subject Evaluability and Subject Replacement 
Subjects in Cohort A are fully evaluable for safety review of the concurrent ipilimumab and 
nivolumab therapy if: 
1) they receive at least 1 dose of ipilimumab, nivolumab, or RT and have a Grade 3 or 4 
related AE 
2) In the absence of a Grade 3 or 4 related AE, they fulfill the criteria for the Per-protocol 
population for safety and tolerability as defined in Section 4.1.2. 
Subjects in Cohort A who are not fully evaluable for safety review will be replaced.   
Subjects are considered evaluable for the secondary efficacy endpoints if they fulfill the Per-
protocol and Intent to treat populations described in Section 4.2.2, or if they discontinue from 
the study due to symptomatic progression, death, or toxicity at any point. 
Subjects who discontinue the study and do not meet evaluability criteria may be replaced. 
3.1.12 Optional Study Treatment Extension 
Treatment extension with nivolumab monotherapy beyond 18 weeks is permitted and will be 
managed at the Investigator’s discretion in accordance with standard practice. Subjects who 
require additional treatment will continue to be followed for efficacy assessments and On Study 
Follow-up (see Section 3.1.16 and Section 3.2). Details of extended nivolumab monotherapy 
administration should be captured on the Drug Administration electronic case report form 
(eCRF). 
3.1.13 Interim Analysis 
An interim analysis of safety will be performed after 9 subjects in Cohort A have completed 
concurrent ipilimumab and nivolumab therapy in order to determine whether to proceed with 
enrollment into Cohort B (see Section 3.1). 
3.1.14 Safety Monitoring and Study Stopping Rules 
In accordance with the Administrative, Legal and Ethical Requirements section of the protocol 
(see Section 7), Safety Monitoring will be performed by an internal data safety monitoring panel, 
consisting of the Principal Investigators (and co-investigators as needed), the Sponsor’s medical 

 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 14 of 70 
monitor, and drug safety personnel from Bristol-Myers Squibb, the provider of the study drugs. 
Additional investigators and staff, or additional Sponsor personnel and consultants, shall 
participate in reviews as indicated. An Independent Data Monitoring Board will not be utilized 
for this open-label study. 
The study will be suspended or possibly stopped prematurely for any of the following reasons: 
1. A death that is unexpected and at least probably related to 1 or more of the study drugs 
and/or RT. 
2. Severe anaphylactic reaction (i.e., with respiratory and cardiovascular failure) to 1 or more 
of the study drugs. 
3. Any events that, in the judgment of the medical monitor, are deemed serious enough to 
warrant immediate review by the data safety monitoring panel.  
4. Any other safety finding assessed as related to 1 or more study drugs that, in the opinion of 
the internal data safety monitoring panel, contraindicates further dosing of study subjects. 
5. Any interim findings that, in the opinion of the Investigators and the Sponsor, suggest that 
the study treatment has no clinical benefit for the subjects. 
General criteria for premature trial termination are outlined in the Administrative Section 7. 
3.1.15 Duration of Study 
Duration of Treatment: 
1 year (subjects benefitting from nivolumab treatment may 
receive continued treatment) 
Enrollment Period: 
2 years 
Length of Study: 
3 years 
Length of Survival Follow-up 
3 years 
3.1.16   On Study and Post-Study Follow-up 
All subjects, whether they complete the study as planned, discontinue treatment, or 
prematurely withdraw from the study as per Section 3.1.10, will be followed as per institutional 
guidelines in accordance with the usual standard of care principles.  
On Study Follow-up will be conducted for 100 days after the last study drug administration 
according to the flowchart in Section 3.2.  Refer to Section 7.1.5 for information on recording 
AEs during the On Study Follow-up. 
In addition to the On Study Follow-up, there will be a Post Study Follow-up, during which clinical 
outcomes data (dates of progression/relapse and survival) will be collected at least every 
12 (± 1) weeks for 3 years after completion of 100-day On Study Follow-up.  For subjects who do 
not continue Post Study Follow-up at one of the study sites after the end of study, the Principal 
Investigators or the clinical team, under the supervision of the Principal Investigator, will obtain 
the data through review of outside records or communication with the subject or his/her 
physician. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 15 of 70 
3.2 Study Flowchart 
Study Section 
Screen 
ing 
Treatment 
Final Assessment 
and Ongoing 
Treatment/ 
Assessmentsd 
On Study 
Follow-upa,e 
Post-Study  
Follow-up 
(Section 3.1.16) 
Study Week 
 
Week 1 
(Cycle 1) 
Week 4 
(Cycle 2) 
Week 7 
(Cycle 3) 
Week 10 
(Cycle 4) 
Week
12 
Week 
14 
Week
16 
Week
18 
2 weeks (± 3 days) 
after last study drug 
30 (±4), 70 (±4) 
and 100-107 days 
after last study 
drug (AEs and 
pregnancy tests) 
(Starts after 
completion of 100-
day On Study 
Follow-up) 
Q12W (± 7 d) for 
3 years  
Study Day 
-28 to 0 
(or as 
stated) 
1 
22 
(± 3) 
43 
(± 3) 
64 
(± 3) 
78 
(± 3) 
92 
(± 3) 
106 
(± 3) 
120 
(± 3) 
Drug Administration Cohort A  
Ipilimumabf IV 
 
X 
X 
X 
X 
 
 
 
 
 
 
 
Nivolumabf IV  
 
X 
X 
X 
X 
X 
X 
X 
X 
Xd 
 
 
Radiotherapyb,f (30 Gy over 10 fractions 
of 3 Gy) 
 
X 
 
 
 
 
 
 
 
 
 
Drug Administration Cohort B 
Ipilimumabf IV 
 
X 
X 
X 
X 
 
 
 
 
 
 
 
Nivolumabf IV  
 
X 
X 
X 
X 
X 
X 
X 
X 
Xd 
 
 
Radiotherapyb,f (27 Gy over 3 fractions 
of 9 Gy) 
 
X 
 
 
 
 
 
 
 
 
 
Tumor & Disease Assessments 
Disease Staging (date/stage at first 
diagnosis and study entry) 
X 
 
 
 
 
 
 
 
 
 
 
 
Disease Assessment by RECIST 1.1 and 
irRECIST 
X 
 
 
 
 
X 
 
 
X 
Xd 
(Week 24, then 
Q12W ± 7 days) 
 
 
Other Procedures & Examinations 
Eligibility Assessment and Informed 
Consent 
X 
 
 
 
 
 
 
 
 
 
 
 
Demographics (including DoB, sex, 
height, race, ethnicity) 
X 
 
 
 
 
 
 
 
 
 
 
 
Medical History  
X 
 
 
 
 
 
 
 
 
 
 
 
Physical Exam (including weight) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xd 
 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 16 of 70 
Study Section 
Screen 
ing 
Treatment 
Final Assessment 
and Ongoing 
Treatment/ 
Assessmentsd 
On Study 
Follow-upa,e 
Post-Study  
Follow-up 
(Section 3.1.16) 
Study Week 
 
Week 1 
(Cycle 1) 
Week 4 
(Cycle 2) 
Week 7 
(Cycle 3) 
Week 10 
(Cycle 4) 
Week
12 
Week 
14 
Week
16 
Week
18 
2 weeks (± 3 days) 
after last study drug 
30 (±4), 70 (±4) 
and 100-107 days 
after last study 
drug (AEs and 
pregnancy tests) 
(Starts after 
completion of 100-
day On Study 
Follow-up) 
Q12W (± 7 d) for 
3 years  
Study Day 
-28 to 0 
(or as 
stated) 
1 
22 
(± 3) 
43 
(± 3) 
64 
(± 3) 
78 
(± 3) 
92 
(± 3) 
106 
(± 3) 
120 
(± 3) 
Electrocardiogram (baseline and as 
clinically indicated) 
X 
 
 
 
 
 
 
 
 
 
 
 
Vital Signs (temperature, HR, BP, RR) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xd 
 
 
ECOG Performance Status 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xd 
 
 
Concomitant Medications/Procedures 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xd 
 
 
Adverse Events Assessment 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xd 
X 
 
Laboratory Measurements & Assays 
Serum Pregnancy Teste  
X 
 
 
 
 
 
 
 
 
Xd,e 
Xe 
 
Urine Pregnancy Test (collected pre-
dose)e 
 
X 
 
X 
 
X 
 
 
X 
(Q6W)d,e 
 
 
Chemistry (Na, K, Cl, CO2, BUN, creat., 
gluc., Ca, Mg, total prot., alb., Tbili., AST, 
ALT, ALP, LDH; blood drawn before 
dosingg 
(-14 to 
0) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xd,g 
 
 
Free T3, Free T4, TSH; blood drawn 
before dosingg 
(-14 to 
0) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xd,g 
 
 
Amylase, lipase; blood drawn before 
dosing 
(-14 to 
0) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xd 
 
 
Blood Hematology (CBC with differential 
and platelets; blood drawn before 
dosing) 
(-14 to 
0) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xd 
 
 
Research Blood Draw (60 mL; blood 
drawn before dosing) 
 
X 
 
X 
 
X 
 
 
 
 
 
 
Tumor Biopsy (optional)c 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 17 of 70 
Study Section 
Screen 
ing 
Treatment 
Final Assessment 
and Ongoing 
Treatment/ 
Assessmentsd 
On Study 
Follow-upa,e 
Post-Study  
Follow-up 
(Section 3.1.16) 
Study Week 
 
Week 1 
(Cycle 1) 
Week 4 
(Cycle 2) 
Week 7 
(Cycle 3) 
Week 10 
(Cycle 4) 
Week
12 
Week 
14 
Week
16 
Week
18 
2 weeks (± 3 days) 
after last study drug 
30 (±4), 70 (±4) 
and 100-107 days 
after last study 
drug (AEs and 
pregnancy tests) 
(Starts after 
completion of 100-
day On Study 
Follow-up) 
Q12W (± 7 d) for 
3 years  
Study Day 
-28 to 0 
(or as 
stated) 
1 
22 
(± 3) 
43 
(± 3) 
64 
(± 3) 
78 
(± 3) 
92 
(± 3) 
106 
(± 3) 
120 
(± 3) 
Progression and Survival Follow-up 
 
 
 
 
 
 
 
 
 
 
 
X 
Abbreviations: alb. = albumin; ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; Tbili. = total bilirubin; BP = blood pressure; BUN = 
blood urea nitrogen; Ca = calcium; CBC = complete blood count; Cl = chloride; CO2 = carbon dioxide; creat. = creatinine; CT = computed tomography; d = day(s); DoB = date of birth; 
ECOG = Eastern Cooperative Oncology Group; eCRF = electronic case report form; gluc. = glucose; Gy = Gray; HR = heart rate; irRECIST = immune-related RECIST; IV = intravenous(ly); 
K = potassium; mL = milliliter(s); LDH = lactate dehydrogenase; Mg = magnesium; Na = sodium; prot. = protein; Q = every; RECIST = Response Evaluation Criteria for Solid Tumors; 
RR = respiratory rate; RT = radiotherapy; W = week(s); Q6W = every 6 weeks; Q12W = every 12 weeks 
Note:  Additional assessments may be evaluated at the Investigator’s discretion and per standard of care. Indicated assessments within this chart define clinical data to be captured 
in the eCRF. Standard of Care procedures may be used for eligibility assessments, provided they meet the criteria specified in either the inclusion criteria or flowchart. 
a Subjects will be followed for 100 days after the last dose of study drug as a part of On Study Follow-up; during this time, all AEs will be collected at 30 (±4), 70 (±4) and 100-107 days.   
b Radiotherapy will be delivered by standard or high dose palliative RT as per cohort assignment.  
c Tumor biopsies are optional but are encouraged. Biopsies are prohibited from compromising the requirement for at least one measurable lesion not undergoing RT. 
d Final Assessment will be 2 weeks (± 3 days) after last study drug, followed by On Study Follow-up and Post Study Follow-up. A repeat disease assessment scan is not required at 
the final assessment visit if a scan was done within the previous 6 weeks before the final assessment visit. Subjects who do not continue treatment with nivolumab after Week 18 
do not need to have a repeat pregnancy test (if applicable) at the final assessment if the subject had this assessment at Week 18.   
For those subjects who are continuing on nivolumab after Week 18 at 240 mg every 2 weeks ±3 days, Study Visits will continue every 2 weeks ± 3 days during treatment, 
followed by the Final Assessment Visit, On Study Follow-up, and Post Study Follow-up after the last nivolumab treatment.  
Per Amendment 5, nivolumab monotherapy continuing after Week 18 may be given as 480 mg every 4 weeks ±3 days, starting on Week 20, followed by Weeks 24, 28, etc. 
For those subjects who are continuing on nivolumab after Week 18 at 480 mg every 4 weeks ±3 days, Study Visits will continue every 4 weeks ± 3 days during treatment, 
followed by the Final Assessment Visit, On Study Follow-up, and Post Study Follow-up after the last nivolumab treatment. 
Subjects continuing nivolumab monotherapy, subjects who complete study treatment as responders, and subjects who have not progressed (either in irradiated or non-irradiated 
tumor burden) will have an additional scan (disease assessments by RECIST 1.1/ irRECIST) at Week 24 and subsequent scans Q12W (± 7 days) until progression or start of 
alternate anti-cancer therapy. 
e For females of child-bearing potential (as defined in Section 5.2), pregnancy tests required every 6 weeks and repeated at 30 (±4) days and 70 (±4) days after discontinuation of 
treatment. Serum pregnancy test is done at screening, final assessment, and during On Study Follow-up; urine pregnancy test is done at all other visits, including during continued 
nivolumab treatment (Note: For females of child-bearing potential who are continuing on nivolumab after Week 18 at 480 mg every 4 weeks, urine pregnancy tests may be done 
every 8 weeks). Urine pregnancy test is done and results confirmed pre treatment on Day 1 of study. 
f All subjects will receive concurrent nivolumab (1 mg/kg) followed by ipilimumab (3 mg/kg) on the same day every 3 weeks for 4 doses, then followed by nivolumab monotherapy 
(240 mg every 2 weeks ±3 days) See footnote d for ongoing nivolumab monotherapy after Week 18.  Radiotherapy will be initiated after the first dose and before the second dose 
of immunotherapy. 
g Per Amendment 5: After Week 18, LDH testing and TSH (with reflexive free T3/T4) testing during ongoing nivolumab treatment will be done as clinically indicated; other testing 
will continue per flowchart.  

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 18 of 70 
4 Study Objectives & Endpoints 
Primary 
Objective 
[Endpoints] 
Safety and Tolerability [According to the NCI CTCAE, Version 4.03] 
Secondary 
Objectives 
[Endpoints] 
 
• ORR by RECIST 1.1 and irRECIST [ORR at Weeks 12 and 18] 
• DCR by RECIST 1.1 and irRECIST [DCR at Weeks 12 and 18] 
• Duration of response 
• PFS 
• OS 
Exploratory 
Objectives 
[Endpoints] 
Antitumor Immunity [Immunological Effects of Ipilimumab/Nivolumab/RT] 
CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events; DCR = disease control rate; 
irRECIST = immune-related RECIST; ORR = objective response rate; OS = overall survival; PFS = progression-free 
survival; RECIST = Response Evaluation Criteria in Solid Tumors; RT = radiotherapy 
4.1 Safety and Tolerability 
The safety and tolerability of ipilimumab and nivolumab in combination with RT will be 
determined. Safety will be evaluated by the internal data safety monitoring panel on an 
ongoing basis, based on data review and regular conference calls with the investigators. 
4.1.1 Endpoints & Assessment Methods 
Clinical laboratory tests, vital sign measurements, physical examinations, and subject interviews 
will be performed to detect new abnormalities and deteriorations of any pre-existing conditions. 
The investigator will evaluate any laboratory abnormalities for clinical significance, and clinically 
significant abnormalities will be recorded as AEs. All treatment-emergent, clinically significant 
abnormalities and deteriorations from the time of informed consent to the End of Study Visit 
should be recorded in the eCRFs as AEs and graded according to the National Cancer Institute 
(NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. 
4.1.2 Subject Evaluation & Statistics 
The Intent-To-Treat (ITT) Population for safety and tolerability is defined as all subjects who 
receive at least one dose of study drug or RT.  The Per-Protocol (PP) Population for safety and 
tolerability is defined as all subjects who received at least 75% of the scheduled doses of study 
drugs and RT over the first 2 cycles, as well as, respective safety assessments (up to and 
including the pre-dose assessments scheduled for Cycle 3) without major protocol violations 
over the entire Cohort A concurrent ipilimumab and nivolumab assessment period (as defined in 
Section 3.1.9).   
For both cohorts, the overall analysis of safety and tolerability will be based on the ITT 
Population. 
Appropriate summaries of AEs, laboratory data, and vital sign data will be presented.  AEs will be 
listed individually per subject according to the NCI CTCAE, Version 4.03, and the number of 
subjects experiencing each AE will be summarized using descriptive statistics. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 19 of 70 
4.2 Clinical Efficacy 
4.2.1 Endpoints & Assessment Methods 
Clinical efficacy will be determined by objective response rate (ORR), disease control rate (DCR), 
duration of response, progression-free survival (PFS), and overall survival (OS). The primary 
method of assessment of tumor response will be the Response Evaluation Criteria for Solid 
Tumors (RECIST) 1.1, and the secondary method of response evaluation will be irRECIST (see 
Section 8.4) 
4.2.1.1 Tumor Response and Overall Response Rate 
4.2.1.1.1 
Tumor Response outside the Irradiated Fields 
ORR will be evaluated at Weeks 12 and 18 as a secondary endpoint of this study.  
Tumor imaging assessments (e.g., CT, MRI, PET, etc.) of chest, abdomen, pelvis, and CNS for 
assessment of tumor size and distribution may be employed as deemed appropriate by 
investigators. Every attempt should be made to use whichever imaging technique(s) test(s) are 
used initially for repeat evaluations throughout the study. End of study tumor assessment will 
be 6 weeks from prior assessment, at the Investigator’s discretion, and in accordance with the 
appropriate evaluation method. 
Radiographic imaging evaluations are considered standard of care for subjects treated with 
ipilimumab/nivolumab. Subjects treated off protocol with apparent progressive disease at 
Weeks 12 or 18 are encouraged to undergo a repeat radiographic assessment of disease 
approximately 4 to 6 weeks later to confirm progression. 
Study radiologists will be informed as to which lesions are intended to undergo RT. The lesions 
undergoing RT will not be included in the total tumor burden assessment. A separate calculation 
of response within the irradiated field will be determined as described in Section 4.2.1.1.2. 
4.2.1.1.2 
Tumor Response within Irradiated Fields 
Since the lesions that undergo RT are not included in the overall tumor burden for purposes of 
overall response assessments, response within the irradiated field will be separately 
determined.   
The determination of response within the irradiated tumor burden is an independent calculation 
from the determination of response overall for the tumor burden that does not receive RT. 
4.2.1.2 Disease Control Rate 
Disease Control Rate (DCR) will be evaluated at Weeks 12 and 18 as a secondary endpoint of this 
study. DCR is defined as the percentage of evaluable subjects with SD, PR, or CR. 
4.2.1.3 Duration of Response 
Duration of response will be determined for each subject with time origin at the first occurrence 
of response until the first occurrence of progression or date of death if the subject dies due to 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 20 of 70 
any causes before progression. Every effort will be made to follow subjects for progression after 
they discontinue the study. 
4.2.1.4 Progression-free Survival 
PFS will be defined as the number of days from the date of the first dose of study drug to the 
date of earliest disease progression based on the appropriate response evaluation method, or to 
the date of death, if disease progression does not occur. Subjects who do not progress and are 
still alive will be censored on the date of last follow-up or start of new treatment, whichever 
comes first. Every effort will be made to follow subjects for progression after they discontinue 
the study. 
4.2.1.5 Overall Survival 
OS will be measured for each subject from the date of the first dose of study drug until the 
recorded date of death or last follow-up. Subjects who are still alive will be censored on the date 
of last follow-up. Every effort will be made to follow subjects for OS after they discontinue the 
study. 
4.2.2 Subject Evaluation & Statistics 
The Intent-To-Treat (ITT) Population for clinical efficacy is defined as all subjects who receive at 
least one dose of study drug or RT.   
The Per-Protocol (PP) Population for clinical efficacy is defined as all subjects who received at 
least 75% of the scheduled doses of the study drug and RT over the first 2 cycles, as well as, 
respective disease assessments, without major protocol violations.   
The analysis will be based on both ITT and PP populations. 
Tumor Response will be summarized and analyzed descriptively for each cohort and analysis 
population.  
Tumor response rates will be assessed overall and for each cohort and tabulated with the 95% 
confidence intervals assuming binomial distribution. 
For time-to-event analyses, Kaplan-Meier methodology will be implemented to estimate the 
median duration of response, median PFS, and median OS at Weeks 12 and 18. 
4.3 Antitumor Immunity 
4.3.1 Endpoints & Assessment Methods 
Exploratory immunologic objectives will be assessed from peripheral blood and tumor biopsy 
samples according to the schedule in Section 3.2 to assess the influence of ipilimumab and 
nivolumab plus RT on assays, which may include but may not be limited to the following: 
• 
Lymphocyte phenotype using markers such as ICOS, PD-1, and CD25; 
• 
Quantities of myeloid-derived suppressor cells (MDSCs), defined as CD14+HLA-DRlow cells; 
• 
Antibody and functional T cell responses to tumor associated antigens (i.e., NY-ESO-1) for 
relevant subjects; 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 21 of 70 
• 
Serum cytokine levels such as TNF-alpha, IFN-gamma, IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-8, 
IL-10, IL-12, and TGF-beta; 
• 
Serum and plasma microparticle and exosome nanoFACS and proteomic profiles; 
• 
T cell repertoire diversity in peripheral blood and tumor. 
Immunologic characteristics will be summarized descriptively. Antibody, T cell phenotype, and 
functional T-cell responses will be assessed. Antibody responses will be measured using ELISA 
and a positive antibody response will be defined as extrapolated reciprocal titers > 100 post 
treatment. Intracellular cytokine staining will be utilized to assess CD4+ and CD8+ T cell 
responses. Samples collected after treatment will be considered positive for response if they are 
higher than baseline values by at least 3 standard deviations. Therefore, for each subject, the 
standard deviation of the pre-treatment at two separate time points (using 6 replicates each) 
will be computed, and a positive will be defined as greater than 3 times this value and greater 
than 0.1% after 10-day in vitro stimulation. 
Additional investigational methods may be used to characterize and measure components of 
the immune response based upon the latest available technology. 
4.4 Additional Exploration of Immune Response 
The methods used to analyze immune response to cancer antigens used in this study are well 
established. However, as cellular biology and immune regulation are very active fields of 
discovery, the opportunity exists to refine and extend the analysis of immune response. 
Therefore, although most of the blood drawn for the analysis of the immune response is 
planned for the assays listed, a small part, if still available, may be used to explore other aspects 
of immunological response. This work may also involve assessing exosomes and markers 
associated with radiation-induced immunologic cell death, such as expression of calreticulin and 
extracellular release of HMGB1. There may also be interest in establishing T-cell lines and clones 
in culture, evaluating tumor antigen-specific immune responses such as those against NY-ESO-1, 
assessing TCR repertoire diversity, proteomics/seromics analyses, and using samples in 
collaborations with other investigators and laboratories including those outside of the Ludwig 
Institute. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 22 of 70 
5 Subject Eligibility 
Note: Standard of Care procedures may be used for eligibility assessments provided they meet 
the criteria specified in either the inclusion criteria or flowchart. 
5.1 Inclusion Criteria 
Eligible subjects must fulfill all of the following criteria: 
1. 
Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can be 
safely irradiated and, in the opinion of the radiation oncologist, is of benefit to the subject 
to irradiate (note: subjects with primary ocular and mucosal melanoma are permitted). 
Lesions may include, but are not limited to: 
a. Symptomatic lymphadenopathy; 
b. Bothersome cutaneous disease; 
c. Hepatic metastases; 
d. Pulmonary metastases. 
2. 
Excluding the lesion intended to undergo radiation, subjects must have at least 1 
unresectable, non-bony lesion that is measurable radiographically (based on RECIST 1.1). 
3. 
Any number of prior therapies (including none). 
For subjects who have received prior systemic treatment with CTLA-4, PD-1, and/or PD-L1 
therapy, the last monoclonal antibody administration should be no less than 4 weeks prior 
to start of this protocol therapy and all prior side effects must have resolved to grade 1 or 
less by the time of the start of this protocol therapy. 
4. 
Subjects must have: 
• 
Completed investigational therapy, other immunotherapy, or prior RT at least 28 days 
before administration of the first dose of study drug(s) 
• 
Completed chemotherapy or targeted therapy at least 14 days before administration 
of the first dose of study drug(s) 
• 
Sufficiently recovered from prior surgery as determined by the treating Investigator. 
Clinically significant toxicity or pharmacodynamic effects experienced during any prior 
therapy must be resolved or stabilized before the first dose of study drug(s). 
5. 
ECOG performance status of 0-1. 
6. 
Life expectancy ≥ 4 months. 
7. 
Screening laboratory parameters: 
a. White blood cell (WBC) count ≥ 2000/µL; 
b. Absolute neutrophil count (ANC) ≥ 1500/µL; 
c. Platelets ≥ 100,000/µL; 
d. Hemoglobin (Hgb) ≥ 9 g/dL; 
e. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper 
limit of normal (ULN); 
f. Total bilirubin ≤ 1.5 × ULN (< 3 mg/dL for subjects with Gilbert’s disease); 
g. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using 
the Cockcroft-Gault formula below): 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 23 of 70 
Female CrCl = [(140 - age in years) x weight in kg x 0.85] / [72 x serum creatinine in mg/dL] 
Male CrCl = [(140 - age in years) x weight in kg x 1.00] / [72 x serum creatinine in mg/dL] 
8. 
Age ≥ 18 years. 
9. 
Able and willing to give valid written informed consent. 
5.2 Exclusion Criteria 
Subjects may not enter the study if they fulfill any of the following criteria: 
1. 
Unresolved irAEs following prior biological therapy.  Subjects with asymptomatic 
endocrinopathy may enroll. 
2. 
Active autoimmune disease or any condition requiring systemic treatment with either 
corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive 
medications within 14 days of study drug administration. Inhaled or topical steroids and 
adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the 
absence of active autoimmune disease. 
3. 
History of motor neuropathy considered to be of autoimmune origin (e.g., Guillain-Barre 
Syndrome, Myasthenia Gravis). 
4. 
Other active, concurrent malignancy that requires ongoing systemic treatment or 
interferes with radiographic assessment of melanoma response as determined by the 
investigator. 
5. 
Active brain metastases or leptomeningeal metastases. Subjects with brain metastases 
are eligible if metastases have been treated and there is no magnetic resonance imaging 
(MRI) evidence of progression for 4 weeks or more after treatment is complete and within 
28 days prior to the first dose of nivolumab administration. There must also be no 
requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day 
prednisone equivalents) for at least 2 weeks prior to study drug administration. 
6. 
Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to 
Hepatitis B or C without evidence of active infection may be allowed. 
7. 
History of severe allergic reactions to any unknown allergens or any components of the 
study drugs. 
8. 
Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders). 
9. 
Requirement of RT to treat brain metastases or receipt of any non-study systemic therapy 
for cancer or any other experimental/investigational treatment. 
10. Mental impairment that may compromise the ability to give informed consent and 
comply with the requirements of the study. 
11. Lack of availability for immunological and clinical assessments or post-study follow-up 
contact to determine relapse and survival.  
12. Women who are breastfeeding or who are pregnant as evidenced by a positive serum 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed within 
14 days of the first dose of study drug and by a urine pregnancy test (minimum sensitivity 
25 IU/L or equivalent units of HCG) within 24 hours of the first dose of study drug(s). 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 24 of 70 
13. Females of childbearing potential who are sexually active with a nonsterilized male 
partner must use 2 methods of effective contraception from screening, and must agree to 
continue using such precautions for 23 weeks after the final dose of investigational 
product; cessation of birth control after this point should be discussed with a responsible 
physician. Periodic abstinence, the rhythm method, and the withdrawal method are not 
acceptable methods of birth control. 
[Females of childbearing potential are defined as those who are not surgically sterile (i.e., 
bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmeno-
pausal (defined as 12 months with no menses without an alternative medical cause).] 
Nonsterilized males who are sexually active with a female partner of childbearing 
potential must use 2 acceptable methods of effective contraception from Day 1 and for 
31 weeks after receipt of the final dose of investigational product. 
Acceptable methods of effective contraception are described in the following table: 
Barrier Methods 
Intrauterine Device Methods Hormonal Methods 
Male condom plus spermicide, 
cap plus spermicide, or 
diaphragm plus spermicide. 
Copper T, or Levonorgestrel-
releasing intrauterine system 
(e.g., Mirena®), also considered a 
hormonal method. 
Implants, hormone shot or 
injection, combined pill, minipill, 
or Patch. 
 
14. Any condition that, in the clinical judgment of the treating physician, is likely to interfere 
with the interpretability of the data or prevent the subject from complying with any 
aspect of the protocol or that may put the subject at unacceptable risk. 
 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 25 of 70 
5.3 Restrictions on Concomitant Therapies 
5.3.1 Non-Permitted Concomitant Therapies 
Subjects may not receive the following concomitant therapies during the study, except as 
allowed in Section 5.3.2: 
1. 
Systemic treatment with high-dose glucocorticosteroids (> 10 mg daily prednisone 
equivalents) or other immunosuppressive treatments (e.g., methotrexate, 
chloroquine, azathioprine, adalimumab), with a wash-out period of 2 weeks prior to 
Day 1, unless such treatment is required to treat potential AEs. 
2. 
Other non-study cancer therapy, with a wash-out period of 4 weeks (2 weeks for 
chemotherapy, 6 weeks for nitrosoureas, and 12 weeks for antibodies other than 
CTLA-4, PD-1, and/or PD-L1 antibodies) prior to Day 1. 
3. 
Any other investigational agents. 
The wash-out period prior to Day 1 of the study for all non-permitted drugs should be at 
least 1 week, unless stated otherwise above. 
5.3.2 Permitted Concomitant Therapies 
Subjects may receive the following concomitant therapies during the study: 
1. 
At the discretion of the investigator, any drug or non-drug therapy necessary to treat 
any condition arising during the study, including high dose corticosteroids to treat 
study-drug-related immune-mediated adverse reactions. Subjects should receive full 
supportive care, including transfusions of blood and blood products, and treatment 
with antibiotics, anti-emetics, anti-diarrheal, and analgesics, and other care as deemed 
appropriate, and in accordance with their institutional guidelines. Use of 
anticoagulants such as warfarin is permitted; however, caution should be exercised 
and additional international normalized ratio (INR) monitoring is recommended. 
Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone 
equivalents are permitted in the absence of active autoimmune disease. 
2. 
As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab 
combinations, drugs with a predisposition to hepatoxicity should be used with caution 
in subjects treated with nivolumab-containing regimens. 
All prescription and nonprescription drugs must be recorded in the concomitant medications 
section of the eCRF, listing generic (preferably) or brand name, indication, dose, route, and 
dates of administration. All non-drug therapies must be recorded in the respective sections 
of the eCRF or as AEs. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 26 of 70 
6 Study Drug Preparation and Administration 
All study drugs are manufactured in accordance with Good Manufacturing Practices (GMP). 
6.1 Ipilimumab and Nivolumab 
The text within this section is provided for guidance; the current nivolumab and ipilimumab 
Investigator Brochures should be consulted for complete information regarding the storage, 
preparation, and administration of the study drugs. 
Ipilimumab and Nivolumab Product Descriptions 
Product 
Description and 
Dosage Form 
Potency 
Primary Packaging 
(Volume)/Label 
Type 
Secondary 
Packaging 
(Qty)/Label Type 
Appearance 
Storage 
Conditions 
(per label) 
Nivolumab 
(BMS-936558-
01) Solution for 
Injectiona 
100 mg 
(10 mg/mL) 
10 mL / vial 
5-10 vials per 
carton/Open-label 
Clear to opalescent 
colorless to pale 
yellow liquid. May 
contain particles 
2 to 8°C; 
Protect from 
light and 
freezing 
Ipilimumab 
Solution for 
Injection 
200 mg 
(5 mg/mL) 
40 mL / vial 
4 vials per 
carton/Open-label 
Clear, colorless to 
pale yellow liquid. 
May contain 
particles 
2 to 8°C; 
Protect from 
light and 
freezing. 
aNivolumab may be labeled as BMS-936558-01 Solution for Injection. 
If stored in a glass front refrigerator, vials should be stored in the carton. Recommended safety 
measures for preparation and handling of nivolumab and ipilimumab include laboratory coats 
and gloves. 
When study drugs (ipilimumab or nivolumab) are to be administered on the same day, separate 
infusion bags and filters must be used for each infusion. It is recommended that nivolumab be 
administered first, as an IV infusion over approximately 60 minutes (or 30 minutes; see note), 
followed by ipilimumab administered as an IV infusion over approximately 90 minutes (or 30 
minutes) that starts approximately 30 minutes after completion of the nivolumab infusion. 
Note: an infusion time of 30 minutes may also be used for each of the drug infusions (i.e., 30-
minute infusion for nivolumab→30-minute interval→30-minute infusion for ipilimumab) as 
described by Martin-Algarra, et al.(46)   
Dosing calculations should be based on body weight. If the subject’s weight on the day of dosing 
differs by > 10% from the weight used to calculate the dose, the dose must be recalculated. All 
doses should be rounded up or to the nearest milligram or as per local institutional standard. 
Due to parameters surrounding the use time of nivolumab and ipilimumab, the time of 
preparation should be noted in the Pharmacy Source documents (accountability logs) or in study 
files as required for investigator-sponsored research (FDA and GCP). 
6.1.1 Nivolumab Storage Conditions & Handling 
• 
Store at 2°C to 8°C (36°F to 46°F); protect from light, freezing, and shaking. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 27 of 70 
• 
Please report any temperature excursions encountered during storage to BMS for 
assessment via the Temperature Excursion Response Form. 
• 
As with all injectable drugs, care should be taken when handling and preparing nivolumab. 
Whenever possible, nivolumab should be prepared in a laminar flow hood or safety cabinet 
using standard precautions for the safe handling of IV agents applying aseptic technique. 
• 
Partially used vials should be disposed of at the site following procedures for the disposal of 
anticancer drugs. 
• 
After final drug reconciliation, unused nivolumab vials should be disposed at the site 
following procedures for the disposal of anticancer drugs. 
For details regarding nivolumab preparation, storage, and administration please refer to the 
pharmacy reference sheets/Investigator Brochure. 
6.1.2 Nivolumab Preparation and Administration 
For details regarding nivolumab preparation, storage, and administration please refer to the 
pharmacy reference sheets/Investigator Brochure. 
1. Visually inspect the drug product solution for particulate matter and discoloration prior to 
administration. Discard if solution is cloudy, if there is pronounced discoloration (solution 
may have a pale-yellow color), or if there is foreign particulate matter other than a few 
translucent-to-white, amorphous particles.  Note: Mix by gently inverting several times. Do 
not shake. 
2. Aseptically withdraw the required volume of nivolumab solution into a syringe, and dispense 
into an IV bag. If multiple vials are needed for a subject, it is important to use a separate 
sterile syringe and needle for each vial to prevent problems such as dulling of needle tip, 
stopper coring, repeated friction of plunger against syringe barrel wall. Do not enter into 
each vial more than once. Do not administer study drug as an IV push or bolus injection. 
3. Add the appropriate volume of 0.9% Sodium Chloride Injection solution or 5% Dextrose 
Injection solution. It is acceptable to add nivolumab solution from the vials into an 
appropriate pre-filled bag of diluent. 
4. Note: Nivolumab infusion concentration must be at or above the minimum allowable 
concentration of 0.35 mg/mL. 
5. Note: It is not recommended that so-called “channel” or tube systems are used to transport 
prepared infusions of nivolumab. 
6. Attach the IV bag containing the nivolumab solution to the infusion set and filter. 
7. At the end of the infusion period, flush the line with a sufficient quantity of approved 
diluents. 
Additional information: 
1. The administration of nivolumab infusion must be completed within 24 hours of 
preparation. If not used immediately, the infusion solution may be stored under 
refrigeration conditions (2°C to 8°C, 36°F to 46°F) for up to 24 hours, and a maximum of 8 
hours of the total 24 hours can be at room temperature (20°C to 25°C, 68°F to 77°F) and 
room light. The maximum of 8 hours under room temperature and room light conditions 
includes the product administration period. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 28 of 70 
2. Nivolumab injection is to be administered as an IV infusion through a 0.2-micron to 1.2-
micron pore size, low-protein binding (polyethersulfone membrane) in-line filter at the 
protocol-specified doses and infusion times. It is not to be administered as an IV push or 
bolus injection. When the dose is based on subject weight (ie, mg/kg), nivolumab injection 
can be infused undiluted (10 mg/mL) or diluted with 0.9% sodium chloride injection, USP or 
5% dextrose injection, USP to protein concentrations as low as 0.35 mg/mL. When the dose 
is fixed (eg, 240 mg or 480 mg flat dose), nivolumab injection can be infused undiluted or 
diluted so as not to exceed a total infusion volume of 120 mL. 
6.1.3 Ipilimumab Storage Conditions & Handling 
For details regarding preparation, storage, and administration please refer to the pharmacy 
reference sheets/Investigator Brochure. 
Ipilimumab injection may be stored undiluted (200 mg/vial [5 mg/mL]) or following dilution to 
concentrations between 1 mg/mL and 4 mg/mL in 0.9% Sodium Chloride Injection (USP), or 5% 
Dextrose Injection (USP) in PVC, non-PVC/ or glass containers for up to 24 hours under 
refrigerated conditions (2°C to 8°C) or at room temperature.  For longer storage, ipilimumab 
should be kept refrigerated (2°C to 8°C) with protection from light. Ipilimumab injection must 
not be frozen. 
Partially used vials or empty vials of ipilimumab injection should be discarded at the site 
according to appropriate drug disposal procedures. 
6.1.4 Ipilimumab Preparation and Administration 
As this is provided for guidance only, please see Investigator brochure for additional information 
regarding preparation and administration. 
1. As ipilimumab is stored long-term at refrigerated temperatures (2°C to 8°C) and protected 
from light, allow the appropriate number of vials of ipilimumab to stand at room 
temperature for approximately 5 minutes. 
2. Ensure that the ipilimumab solution is clear, colorless and essentially free from particulate 
matter on visual inspection. If multiple vials are needed for a subject, it is important to use a 
separate sterile syringe and needle for each vial to prevent problems such as dulling of 
needle tip, stopper coring, repeated friction of plunger against syringe barrel wall, etc. 
3. Aseptically transfer the required volume of ipilimumab solution into a syringe. [Note: A 
sufficient excess of ipilimumab is incorporated into each vial to account for withdrawal 
losses.] 
4. Do not draw into each vial more than once. Discard partially used vials or empty vials. 
5. Ipilimumab solution should be added to an appropriate size infusion container to 
accommodate the calculated final volume. Total dose should be calculated using the most 
recent subject weight; if weight on dosing day differs by 10% from prior weight used to 
calculate dosing, the dose should be recalculated and study drug adjusted accordingly. 
6. Mix by GENTLY inverting several times. DO NOT shake.   
7. Ipilimumab injection may be diluted in 0.9% Sodium Chloride Injection, USP or 5% Dextrose 
Injection, USP. 
8. Visually inspect the final solution. If the initial diluted solution or final solution for infusion is 
not clear or contents appear to contain precipitate, the solution should be discarded. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 29 of 70 
9. Immediately after the infusion is complete, flush with an adequate amount of 0.9% Sodium 
Chloride injection (USP) or 5% Dextrose injection (USP) to completely flush the residual fluid 
(dead space) in your administration set (approximately 30 to 50 mL); this will ensure that all 
active drug is delivered to the study participant. 
10. Safely discard any unused portion of the infusion solution. Do not store for reuse. 
Ipilimumab should be administered under the supervision of a physician experienced in the use 
of IV agents. Ipilimumab is administered as an IV infusion only. 
It is possible that sites may have more than one ipilimumab clinical study ongoing at the same 
time. It is imperative that only product designated for this protocol be used for this study. 
6.2 Radiotherapy 
RT will be initiated after the first and before the second dose of ipilimumab/nivolumab. 
Target volumes for RT will be defined in accordance with International Commission on Radiation 
Units and Measurements (ICRU) Report #50: Prescribing, Recording and Reporting Photon Beam 
Therapy, and ICRU Report #71: Prescribing, Recording and Reporting Electron Beam Therapy. 
The target lesion for RT will be defined as the gross tumor volume (GTV). The clinical target 
volume (CTV) will be the same as the GTV. The planning target volume (PTV) will be a minimum 
volumetric expansion of the GTV by 2 mm (5 mm recommended), but ultimately will be left to 
the discretion of the attending radiation oncologist. 
CT simulation will be performed for planning purposes. Details of the CT simulation (4D CT, 
gating, use of contrast, immobilization) will be left to discretion of the attending radiation 
oncologist. 
RT will be planned in 3-D and may be delivered using conventional, IMRT or rapid arc 
methodology. 6-18 MV photons and/or electron beam RT will be used as determined by the 
specific clinical situation. 95% of the PTV should receive the prescription radiation dose. Normal 
tissue constraints (see Section 8.5) will not be exceeded during the planning process. 
When photon therapy is used, portal imaging, cone beam CT, or 2D kV on board imaging for QC 
will occur for each treatment. When electron therapy is used, light field verification of the target 
will occur at the start of treatment. 
6.3 Drug Overdose Management 
Any overdoses with the study drugs should be managed according to the appropriate package 
inserts. All overdoses (excess of 10% or more) must be reported, with or without associated 
AEs/serious adverse events (SAEs), according to Section 7.1.5 and Section 7.1.6. 
 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 30 of 70 
7 Administrative, Legal & Ethical Requirements 
7.1 Documentation and Reporting of Adverse Events 
7.1.1 General AE/SAE Definitions per ICH Guidelines 
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and that does not necessarily have a causal 
relationship with the treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product. 
N.B.: The definition above, provided for in the GCP-ICH Guideline E6, is being extended for the 
purpose of LICR studies to include any events, intercurrent diseases and accidents observed 
while the subject is on study, i.e., during the actual treatment period, as well as during drug-
free, pre- and post-treatment periods.,  
A Serious Adverse Event (SAE) is any untoward medical occurrence that: 
1. Results in death, 
2. Is life-threateningA, 
3. Requires inpatient hospitalization or prolongation of existing hospitalization, 
4. Results in persistent or significant disability or incapacity, 
5. Is a congenital anomaly / birth defect or 
6. Is another medically important conditionB. 
A 
The term “life-threatening” in the definition of “serious” refers to an event in which the 
patient/subject is at risk of death at the time of the event; it does not refer to an event, 
which hypothetically might have caused death if it were more severe. 
B 
Medically important conditions that may not result in death, be immediately life-
threatening or require hospitalization may be considered as SAE when, based upon 
appropriate medical judgment, they may jeopardize the patient/subject or may require 
intervention to prevent one of the outcomes listed in the definition above. Examples of such 
events are intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or 
development of drug dependency or drug abuse. 
N.B.: The term “severe” is often used to describe the intensity (severity) of an event (such as: 
mild, moderate, or severe, e.g., pain). The event itself may be of relatively minor medical 
significance (such as severe headache). This is not the same as “serious”, which is based on 
subject/event outcome or action criteria usually associated with events that pose a threat to 
subject’s life or vital functions. Seriousness (not severity) serves as a guide for defining 
regulatory reporting obligations. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 31 of 70 
7.1.2 Additional SAE Definitions for this Study 
For the purpose of this study, the following events are considered medically important 
conditions and must be treated as SAEs: 
1. Pregnancy. 
2. Overdose (as defined in Section 6.3). 
3. Potential drug-induced liver injury (DILI). 
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities 
should occur prior to the reporting of a potential DILI event. All occurrences of potential 
DILIs, meeting the defined criteria, must be reported as SAEs. Potential DILI is defined as: 
• 
ALT or AST elevation > 3 times upper limit of normal (ULN); AND 
• 
Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum 
alkaline phosphatase); AND 
• 
No other immediately apparent possible causes of AST/ALT elevation and 
hyperbilirubinemia, including, but not limited to, viral hepatitis, pre-existing chronic or 
acute liver disease, or the administration of other drug(s) known to be hepatotoxic. 
4. Suspected transmission of an infectious agent (e.g., pathogenic or nonpathogenic) via the 
study drug. 
7.1.3 Severity of an Adverse Event 
The severity of all serious and non-serious AEs should be assessed according to the NCI CTCAE 
Scale (Version 4.03). 
7.1.4 Relationship of Adverse Events to Study Drug 
The relationship of all serious and non-serious AEs to the investigational agent(s) will be 
determined by the Investigator on the basis of their clinical judgment, using one of the following 
terms (in accordance with NCI Guideline “Expedited Adverse Event Reporting Requirements for 
NCI Investigational Agents”, NCI Cancer Therapy Evaluation Program, January 2001): 
Definitely related (The AE is clearly related to the investigational agent) 
Probably related (The AE is likely related to the investigational agent) 
Possibly related (The AE may be related to the investigational agent) 
Unlikely related (The AE is doubtfully related to the investigational agent) 
Unrelated (The AE is clearly not related to the investigational agent) 
N.B.: When making the assessment on causality, it should be taken into consideration that 
immune-therapeutic agents have the potential to cause very late and/or permanent effects on 
the immune system, i.e., a causal relationship could exist despite a lack of apparent temporal 
relationship. Information provided in the IB and/or in Section 1 (Background) of this protocol 
may support these evaluations. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 32 of 70 
7.1.5 General Reporting Requirements 
Documentation of serious and non-serious AEs includes: dates of onset and resolution, severity, 
seriousness, study drug intervention, treatment and outcome, as well as the causal relationship 
between the event and the study drug in accordance with Section 7.1.4. 
All serious and non-serious AEs occurring between the date of signing the informed consent and 
the off-study date must be documented in the source records and on the respective section of 
the CRF, regardless of the assumption of a causal relationship. 
During the On Study Follow-up period, all AEs (not only those deemed to be treatment-related) 
will continue to be collected for 100 days after the last dose of study drug administration. 
7.1.6 Expedited Serious Adverse Event (SAE) Reporting Requirements 
In addition to the General Reporting Requirements specified in Section 7.1.5, all SAEs, 
irrespective of suspected causation, must be reported by the Investigator to the Sponsor 
within 24 hours of discovery, using the “Initial Serious Adverse Event Report Form”, provided 
by the Sponsor, or, if Medidata RAVE data capture is utilized, using the respective eCRFs. This 
includes any deaths that occur after the off-study date, but within 100 days of last study drug 
administration. 
Events meeting the criteria for an SAE as per Sections 7.1.1 and 7.1.2 must be reported to the 
Sponsor’s Drug Safety Contact (primarily) or, alternatively, the Primary Sponsor Contact, via 
email or phone call within 24 hours of becoming aware of the event. The event must also be 
recorded in the Adverse Event Log electronic CRF and indicated as an SAE within 24 hours. 
Studies utilizing the Medidata “Safety Gateway”, built into the eCRF, and respective SAE 
reporting procedures, do not require reporting by fax or email. Questions related to “Safety 
Gateway” procedures should be directed to the Drug Safety Contact or Primary Sponsor Contact 
(see table below). 
In urgent cases, pre-notification via phone or informal e-mail should be considered. 
Drug Safety Contact: 
Gary O’Donnell, MS 
Senior Manager, Drug Safety 
Clinical Trials Management 
Ludwig Institute for Cancer Research 
666 3rd Ave 28th Floor 
New York, New York 10017 
Tel: 
+1 212 450 1551 
Fax: 
+1 212 450 1535 
godonnell@licr.org 
Primary Sponsor Contact: 
Mary Macri 
Director 
Clinical Trials Management 
Ludwig Institute for Cancer Research 
666 3rd Ave 28th Floor 
New York, New York 10017 
Tel: 
+212 450 1546 
Fax: 
+212 450 1535 
mmacri@licr.org 
 
SAEs must also be reported by the Principal Investigator to the respective Institutional Review 
Board after being assigned an SAE tracking number by the Sponsor. Institutional Review Boards 
may have specific rules on which AEs need to be reported expeditiously, as well as, the time 
frames for such reporting. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 33 of 70 
SAE Reports will be evaluated by the Sponsor’s Medical Monitor. Regulatory authorities and 
other investigators, as well as institutional and corporate partners, will be informed by the 
Sponsor as required by ICH guidelines, laws and regulations in the countries where the 
investigational agent is being administered. In particular, SAEs that are unexpected and for 
which a causal relationship with the study drug(s) cannot be ruled out, will be reported by the 
Sponsor within 15 calendar days; if they are life-threatening or fatal, they will be reported within 
7 Calendar days. 
7.1.7 Serious Adverse Event (SAE) Follow-up Requirements 
Subjects experiencing SAEs should be followed closely until the condition resolves or stabilizes, 
and every effort should be made to clarify the underlying cause. Follow-up information related 
to SAEs must be submitted to the Sponsor as soon as relevant data are available, using the “SAE 
Follow-up Report form”, provided by the Sponsor. 
7.2 Administrative Sponsor Requirements 
7.2.1 Study Master Files 
The Investigator must retain a Sponsor-specified comprehensive and centralized filing system 
(“Study Master File”) of all trial-related documentation that is suitable for inspection by the 
Sponsor and regulatory authorities. Upon completion of the trial, the Investigator is required to 
submit a summary report to the Sponsor. 
The Investigator must arrange for the retention of the Study Master File for a period of time 
determined by the Sponsor. No part of the Study Master File shall be destroyed or relocated 
without prior written agreement between the Sponsor and the Investigator. 
7.2.2 Case Report Form Data Collection 
Electronic CRFs will be completed in accordance with respective guidance and after training 
provided by the Sponsor. The use of eCRFs encompasses electronic data entry, query 
management and sign-off. Systems used for electronic data capture will be compliant with FDA 
regulations 21 CFR Part 11 and within the constraints of the applicable local regulatory agency 
guidelines (whichever provides the greatest protection to the integrity of the data). 
All subjects who sign an informed consent form, regardless of study procedures performed, will 
be assigned a screening number and have their data entered into the eCRF. 
The Investigator will sign and date the completed eCRF sections. This signature will indicate a 
thorough inspection of the data in the CRF and will certify its content. 
7.2.3 Language 
The protocol is written in English. All correspondence between the study site and the Sponsor 
should be maintained in English. eCRFs must be completed in English. All written material to be 
used by subjects and para-clinical staff must use vocabulary that is clearly understood, and be in 
the language appropriate for the trial site. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 34 of 70 
7.2.4 Monitoring 
The Sponsor will oversee the conduct of the study and perform clinical monitoring visits for site 
qualification, site initiation, routine monitoring and site close-out. Clinical Monitors and/or 
other sponsor staff will meet with the investigator staff and require direct access to source 
data/documents. Such access may also be required for Institutional Review Board review, and 
regulatory inspection/audits. Direct access is defined as permission to examine, analyze, verify, 
and reproduce any records and reports that are important to the evaluation of the study. All 
reasonable precautions within the constraints of the applicable regulatory requirement(s) to 
maintain the confidentiality of subjects’ identities and sponsor’s proprietary information will be 
exercised. 
It is the Clinical Monitor’s responsibility to inspect the eCRF at regular intervals throughout the 
trial to verify adherence to the protocol, the completeness, accuracy and consistency of the 
data, and adherence to Good Clinical Practice guidelines. The Clinical Monitor should have 
access to subject charts, laboratory reports and other subject records needed to verify the 
entries on the eCRF (“source data verification”). 
7.2.5 Protocol Amendments 
Protocol amendments may be implemented only after approval by the Investigator, Sponsor, 
Institutional Review Board and, if required, the regulatory authorities. Amendments that are 
intended to eliminate an apparent immediate hazard to subjects may be implemented prior to 
such approvals. However, in this case, approval must be obtained as soon as possible after 
implementation. Implementation of administrative amendments that do not affect the safety of 
the subjects do usually not require prior Institutional Review Board approval, just notification. 
When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to 
subjects, the Investigator will contact the sponsor if circumstances permit, to discuss the 
planned course of action. Any departures from the protocol must be fully documented in the 
source documentation. 
7.2.6 Premature Subject Withdrawal 
A subject may withdraw from the study at any time for any reason without prejudice to his/her 
future medical care by the physician or at the study site. Likewise, the Investigator and/or 
Sponsor have the right to withdraw subjects from the study. Specific subject withdrawal reasons 
are listed in Section 3.1.10. Should a subject (or a subject’s legally authorized representative) 
decide to withdraw, all efforts will be made to complete the required study procedures and 
report the treatment observations as thoroughly as possible. 
A complete final evaluation should be made at the time of the subject’s withdrawal, the 
appropriate form in the eCRF should be completed with an explanation of why the subject is 
withdrawing, and an attempt should be made to perform a follow-up evaluation. 
7.2.7 Early Trial Termination 
“End of study” is defined as the last visit of the last subject. Sponsor and Investigator have the 
right to terminate the study early. Specific study stopping rules are listed in Section 3.1.14. In 
such case, one party must notify the other in advance in writing about the intent of and the 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 35 of 70 
reasons for the termination. The investigator must also notify the appropriate Institutional 
Review Board accordingly. 
7.2.8 Study Drug Shipments & Accountability 
Study drug shipments will be addressed to the Principal Investigator’s authorized designee, 
preferably the site’s pharmacy. The recipient will verify the amount and condition of the drug 
and will return a signed Acknowledgment of Receipt to the shipper. 
Initial Orders: 
• 
Following submission and approval of the required regulatory documents, a supply of 
nivolumab and ipilimumab may be ordered from by completing a Drug Request Form 
provided by BMS for this specific trial.  
• 
The initial order should be limited to the amount needed for 2 doses. Allow 5 business days 
for shipment of drug from BMS receipt of the Drug Request Form. Drug is protocol specific, 
but not subject specific. All drug products will be shipped by courier in a temperature-
controlled container. It is possible that sites may have more than one nivolumab clinical 
study ongoing at the same time. It is imperative that only drug product designated for this 
protocol number be used for this study. 
• 
Pharmacy supplies not provided by BMS: Empty IV bags/containers, approved diluents, 
in-line filters, and infusion tubing. 
Re-Supply: 
• 
Drug re-supply request form should be submitted electronically at least 7 business days 
before the expected delivery date. Deliveries will be made Tuesday through Friday. 
• 
When assessing need for resupply, institutions should keep in mind the number of vials used 
per treatment dose, and that shipments may take 14 business days from receipt of request. 
Drug is not subject-specific. Be sure to check with your pharmacy regarding existing 
investigational stock to assure optimal use of drug on hand. 
Drug Excursions: 
• 
Drug excursions should be reported immediately to BMS on the form provided with the 
study-specific drug order form. 
A drug dispensing log (inventory) will be kept by the study site, containing at least the following: 
• 
the subject’s identification (subject number and code) 
• 
date and quantity of drug dispensed 
• 
date and quantity of drug returned to the investigator/pharmacy (if applicable) 
• 
date and quantity of accidental loss of drug (if any)  
These inventories must be made available for inspection by the Clinical Monitor. The 
Investigator is responsible for the accounting of all used and unused trial supplies. At the end of 
the study, the Clinical Monitor will also collect the original study drug dispensing records. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 36 of 70 
At the end of the study or as directed by the Sponsor, all used and unused supplies, including 
partially used or empty containers, will be disposed of or transferred as instructed by the 
Sponsor, and in accordance with local written procedures, if applicable. Any disposal or transfer 
of investigational agent shall be noted on the investigational drug disposition log and signed-off 
by a second person. At the end of the study, the Clinical Monitor will collect the original drug 
disposition logs. 
7.3 Regulatory, Legal, & Ethical Requirements 
7.3.1 Good Clinical Practice (GCP), Laws and Regulations 
The investigator must ensure that he/she and all authorized personnel for the study are familiar 
with the principles of Good Clinical Practice (GCP) and that the study is conducted in full 
conformity with the current revision of the Declaration of Helsinki, ICH Guidelines and 
applicable local laws and regulations, with the understanding that local laws and regulations 
take precedence over respective sections in the Declaration of Helsinki and/or the ICH 
Guidelines. 
7.3.2 Informed Consent 
The investigator must obtain witnessed (if applicable) written informed consent from the 
subject or the subject’s legally authorized representative after adequate explanation of the 
aims, methods, anticipated benefits, and potential hazards of the study and before any study-
specific procedures are performed. The subject should be given a copy of the informed consent 
documentation. The original signed and dated informed consent form must be retained in the 
study records at the study site, and is subject to inspection by representatives of the Sponsor, or 
representatives from regulatory agencies. 
7.3.3 Institutional Review Board 
The investigator must obtain written approval from the appropriate Institutional Review Board 
for the protocol and informed consent, and all amendments thereof, prior to recruitment of 
subjects and prior to shipment of investigational agents. 
The investigator must report SAEs to the appropriate Institutional Review Board in accordance 
with the Institutional Review Board’s rules and guidelines (see also Section 7.1). 
The investigator must assure that continuing review (at least once per year) of the study is 
performed by the Institutional Review Board throughout the duration of the study. If so 
required by the Institutional Review Board, the investigator must provide study reports on an 
annual basis and upon completion of the study. 
All correspondence with, and reports to, the Institutional Review Board must be maintained in 
the study files at the study site and copies must be sent to the Sponsor. 
7.3.4 Subject Confidentiality 
The investigator must ensure that the subject’s privacy is maintained. A subject should only be 
identified by their initials, date of birth and subject number on the eCRF or other documents 
submitted to the Sponsor. Documents that are not submitted to the Sponsor (e.g., signed 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 37 of 70 
informed consent form) should be kept in a strictly confidential section of the study file by the 
Investigator. 
The investigator shall permit the Sponsor and authorized representatives of regulatory agencies 
to review the portion of the subject’s medical record that is directly related to the study. As part 
of the informed consent process, the subject must have given written consent that his/her 
records will be reviewed in this manner. 
 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 38 of 70 
8 Appendices 
8.1 Protocol Version History 
Original issue 
Issue date: 18-SEP-2015 
Summary of Changes: n/a 
 
Amendment 001 
Issue Date:  05-FEB-2016 
Summary of Changes: 
Based on recommendations from institutional reviews, the following changes were made: 
• 
Administrative changes 
o Updated footer and synopsis page with new protocol format and logo. 
o General spelling, capitalization, and formatting changes, as needed. 
• 
Synopsis, Section 3.2 and Section 4: all references to Quality of Life Assessments by 
Functional Assessment of Cancer Therapy-Melanoma (FACT-M) and Brief Pain Inventory-
Short Form were deleted.  Sections 4.3, 8.7, and 8.8, which were related to these 
assessments, were deleted and other sections were re-numbered as appropriate.  The QoL 
assessments were removed from the protocol because it was decided that the low subject 
numbers would preclude a robust statistical analysis. 
• 
Section 3.1.12: added reference to Section 3.2. 
• 
Section 3.1.16: Clarification was added to indicate that Post Study Follow-up will start after 
completion of the 100-day On Study Follow-up. 
• 
Section 3.2, Study Flowchart: 
o A Final Assessment visit was added, and the assessments from On Study Follow-up 
were moved to the Final Assessment visit.   
o Clarification was provided that the On Study Follow-up will be assessed at 30, 70 and 
100 days after last study drug; AEs and pregnancy tests will be assessed as indicated by 
footnotes “a” and “e.”  
o 30, 70 and 100 day assessments were added to footnote “a.” 
o The following clarification was provided as footnote “d”: “Final Assessment will be 2 
weeks after last study drug, followed by On Study Follow-up and Post Study Follow-up. 
For those subjects who are continuing on nivolumab, Study Visits will continue Q2W ± 
3 days during treatment, followed by the Final Assessment Visit, On Study Follow-up, 
and Post Study Follow-up after last nivolumab treatment. Disease assessments by 
RECIST 1.1/ irRECIST will continue Q6W during the continued nivolumab treatment. 
o Clarification was added to indicate that Post Study Follow-up will start after completion 
of the 100-day On Study Follow-up  
o Chemistry and hematology lab assessments were added for Weeks 14 and 16 
o Amylase and lipase assessments were added on the same days as other chemistry 
profile assessments 
o Free T3, Free T4 and TSH were separated from the routine chemistry profile and placed 
on a separate line. 
• 
Section 4.3.1 (previously 4.4.1) and Section 8.6 : Deleted “Whole exome sequencing for 
mutational load and neoantigens pre- and post-RT” from the list of correlative testing to be 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 39 of 70 
done. In addition, it was clarified that the assays may include but may not be limited to the 
list provided. 
• 
Section 5.1, Inclusion Criterion #1 was changed as follows (changes in bold): “Histologic 
diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can be safely 
irradiated and, in the opinion of the radiation oncologist, is of benefit to the subject to 
irradiate...” 
• 
Section 5.2, Exclusion Criterion #1 (Any contraindications for ipilimumab (Yervoy®) or 
nivolumab (Opdivo®) as per the package inserts.) was deleted; remaining criteria were re-
numbered.  
• 
Section 5.3.1, #2: Added clarification that washout period is 6 weeks for CTLA-4, PD-1, 
and/or PD-L1 antibodies and 12 weeks for other antibodies. 
• 
Section 6.1, third paragraph was changed to allow for a time interval for the study drug 
administration time:  a) 60-minute IV infusion was changed to “an IV infusion over 
approximately 60 minutes”; b) 90-minute IV infusion was changed to “an IV infusion over 
approximately 90 minutes.” 
• 
Section 6.1, next to last paragraph was changed as follows (changes in bold and 
underlined): “Dosing calculations should be based on body weight. If the subject’s weight 
on the day of dosing differs by > 10% from the weight used to calculate the dose, the dose 
must be recalculated. All doses should be rounded up or to the nearest milligram or as per 
local institutional standard.” 
• 
Section 7.1.6: Changed Primary Sponsor Contact from Nerely A Cruz to Mary Macri. 
 
Amendment 2 
Issue Date:  06-MAY-2016 
Summary of Changes: 
• 
Cover Page:  IND # was deleted, as this study is exempt. BMS reference number was added. 
• 
Section 3.1.15: Enrollment period was changed from 1 year to 2 years; Length of Study was 
change from 2 to 3 years. 
• 
Section 3.2, Flowchart: 
o “and pre-existing conditions” was deleted from the Medical History line. 
o Added Mg and LDH to list of chemistry assessments 
o Added the following statement to the Note in the footnote:  “Standard of Care 
procedures may be used for eligibility assessments provided they meet the criteria 
specified in either the inclusion criteria or flowchart.” 
o Collection of serum or urine pregnancy tests was clarified in footnotes and flowchart. 
The following statement was added to footnote e: “Serum pregnancy test is done at 
screening, final assessment, and during On Study Follow-up; urine pregnancy test is 
done at all other visits, including during continued nivolumab treatment.”   
o Moved Week 14 urine pregnancy test to Week 12. 
o The following clarification was added to footnote “d” (changes in bold):  “Disease 
assessments by RECIST 1.1/ irRECIST will continue Q6W (starting 6 weeks after last 
disease assessment) during the continued nivolumab treatment. Subjects who do not 
continue treatment with nivolumab after Week 18 do not need to have a repeat 
pregnancy test (if applicable) or disease assessment at the final assessment if the 
subject had these assessments at Week 18.”  

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 40 of 70 
• 
Sections 4.3.1 and 8.6: deleted references to plasma miRNA levels and circulating cell free 
DNA quantity. 
• 
Section 5: added the following Note to Subject eligibility: “Standard of Care procedures 
may be used for eligibility assessments provided they meet the criteria specified in either 
the inclusion criteria or flowchart.”   
• 
Section7.2.2: The following statement was added: “All subjects who sign an informed 
consent form, regardless of study procedures performed, will be assigned a screening 
number and have their data entered into the eCRF.” 
• 
Administrative changes: General spelling, grammar, capitalization, and formatting changes, 
as needed. 
 
Amendment 3 
Issue Date:  10-NOV-2016 
Summary of Changes: 
• 
Synopsis and Section 3.1 (Study Design): Second sentence was modified (changes in bold): 
All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 
3 weeks for 4 doses, followed by nivolumab monotherapy (3 mg/kg 240 mg) every 2 weeks.  
RATIONALE: monotherapy dose for continuing nivolumab was changed from 3 mg/kg to 
fixed dose of 240 mg according current BMS prescribing information.  
• 
Section 3.1 (Study Design) and Section 3.1.9 (Dose-limiting toxicity): The following note was 
added to Cohort A: “Note: Grade 3 or 4 amylase or lipase abnormalities that are not 
associated with clinical symptoms will not be included in the Cohort A safety assessment 
described above.”  A reference to this note was provided in the Synopsis and in Section 
3.1.6 (Sample Size and Statistical Considerations). 
RATIONALE: amylase and lipase can increase to Grades 3/4 without serious issues (e.g., 
pancreatitis) being diagnosed.  
• 
Section 3.1.7 (Treatment Arms and Treatment Schema): The monotherapy dose for 
continuing nivolumab was changed from 3 mg/kg to fixed dose of 240 mg as indicated 
above.  Footnote b was modified (changes in bold):  Administered once every 3 weeks for 4 
doses (at 1 mg/kg) and then 240 mg once every 2 weeks. See Section 6.1 for order of 
infusion. 
• 
Section 3.1.8 (Dosing Adjustments Delays and Discontinuations) and Section 8.5.6 
(Radiotherapy timing and dose fractionation): the following statement was added: “Dose 
modifications for radiotherapy as a result of toxicity are allowed per the Investigator’s 
assessment.” 
• 
Section 3.2 (Flowchart): For the On Study Follow-up visits, the following windows were 
added (changes in bold): 30 (±4), 70 (±4) and 100-107 days after last study drug. 
• 
Section 3.2 (Flowchart): Footnote f was added to clarify the dosing for nivolumab and 
ipilimumab: “All subjects will receive concurrent nivolumab (1 mg/kg) followed by 
ipilimumab (3 mg/kg) on the same day every 3 weeks for 4 doses, then followed by 
nivolumab monotherapy (240 mg) every 2 weeks.  Radiotherapy will be initiated after the 
first dose and before the second dose of immunotherapy.” 
• 
Section 5.1 (Inclusion Criteria):  
o #3 was changed as follows (6 weeks changed to 4 weeks): Any number of prior therapies 
(including none). For subjects who have received prior systemic treatment with CTLA-4, 
PD-1, and/or PD-L1 therapy, the last monoclonal antibody administration should be no 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 41 of 70 
less than 6 4 weeks prior to start of this protocol therapy and all prior side effects must 
have resolved to grade 1 or less by the time of the start of this protocol therapy. 
o #4 was changed FROM: “Subjects must have completed chemotherapy, targeted 
therapy, investigational therapy, other immunotherapy, prior RT, or major surgery 
(requiring general anesthesia) at least 28 days before administration of the first dose of 
study drug(s). Subjects undergoing minor surgical procedures and biopsies that do not 
require general anesthesia may begin receiving study therapy if sufficiently recovered as 
determined by the treating investigator. Clinically significant toxicity experienced during 
any prior therapy must be resolved or stabilized before the first dose of study drug(s).”   
TO:  
“Subjects must have: 
• 
Completed investigational therapy, other immunotherapy, or prior RT at least 28 
days before administration of the first dose of study drug(s) 
• 
Completed chemotherapy or targeted therapy at least 14 days before 
administration of the first dose of study drug(s) 
• 
Sufficiently recovered from prior surgery as determined by the treating 
Investigator. 
Clinically significant toxicity or pharmacodynamic effects experienced during any prior 
therapy must be resolved or stabilized before the first dose of study drug(s).” 
• 
Section 6.1 (Ipilimumab and Nivolumab): the following paragraph was modified (changes in 
bold):  “When study drugs (ipilimumab or nivolumab) are to be administered on the same 
day, separate infusion bags and filters must be used for each infusion. It is recommended 
that nivolumab be administered first, as an IV infusion over approximately 60 minutes (or 
30 minutes; see note), followed by ipilimumab administered as an IV infusion over 
approximately 90 minutes (or 30 minutes) that starts approximately 30 minutes after 
completion of the nivolumab infusion. Note: an infusion time of 30 minutes may also be 
used for each of the drug infusions (i.e., 30-minute infusion for nivolumab→30-minute 
interval→30-minute infusion for ipilimumab) as described by Martin-Algarra, et al.(46)”  
RATIONALE:  the reduced infusion times are based on recommendations from BMS and 
data presented at ESMO 2016 by Martin-Algarra, et al. (46)  
 
Amendment 4 
Issue Date:  10-MAY-2017 
Summary of Changes: 
• 
Synopsis and Section 3.1.6 (Sample Size and Statistical Considerations): for paragraph 2, 
sentence 2, the following clarification was added (changes in bold): “(see exception in 
Section 3.1, i.e., asymptomatic amylase and lipase abnormalities are not included).  
• 
Section 3.1.9 (DLT): the following statement was added to provide clarification for the 
safety evaluation period: “The Cohort A assessment period for this evaluation will include 
the first 2 cycles of treatment, up to and including the pre-dose safety assessments 
scheduled for Cycle 3 (see Section 4.1.2).” 
• 
Section 3.1.11 (Subject Evaluability and Replacement): clarification was provided to 
indicated that the AEs in points 1 and 2 are “related” AEs. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 42 of 70 
• 
Section 3.2, Flowchart: 
o The disease assessment frequency after Week 18 was changed from Q6W to Q12W 
(specifically, ”Week 24, then Q12W ± 7 days), based on Investigator input that Q6W 
scanning is too frequent for patients who have had a response or stable disease after 
their first 24 weeks on study. 
o Footnote d was changed to align with the change for disease assessment (changes in 
bold): “Final Assessment will be 2 weeks (± 3 days) after last study drug, followed by On 
Study Follow-up and Post Study Follow-up. A repeat disease assessment scan is not 
required at the final assessment visit if a scan was done within the previous 6 weeks 
before the final assessment visit. Subjects who do not continue treatment with 
nivolumab after Week 18 do not need to have a repeat pregnancy test (if applicable) 
at the final assessment if the subject had this assessment at Week 18.   For those 
subjects who are continuing on nivolumab, Study Visits will continue Q2W ± 3 days 
during treatment, followed by the Final Assessment Visit, On Study Follow-up, and Post 
Study Follow-up after the last nivolumab treatment. Subjects continuing nivolumab 
monotherapy and subjects who complete study treatment as responders will have an 
additional scan (disease assessments by RECIST 1.1/ irRECIST) at Week 24 and 
subsequent scans Q12W (± 7 days) until progression or start of alternate anti-cancer 
therapy. Disease assessments by RECIST 1.1/ irRECIST will continue Q6W (starting 6 
weeks after last disease assessment) during the continued nivolumab treatment. 
Subjects who do not continue treatment with nivolumab after Week 18 do not need 
to have a repeat pregnancy test (if applicable) or disease assessment at the final 
assessment if the subject had these assessments at Week 18.” 
o Post Study Follow-up frequency was changed for Q24W to Q12W to align with disease 
assessment frequency.  This was also changed in Section 3.1.16. 
o Added “Electrocardiogram (baseline and as clinically indicated)” to allow for a baseline 
for cardiac monitoring. 
o Study week row was clarified to indicate week vs cycle (changes in bold): 
Study Week 
 
Week 1 
(Cycle 1) 
Week 4 
(Cycle 2) 
Week 7 
(Cycle 3) 
Week 10 
(Cycle 4) 
Week 
12 
Week 
14 
Week 
16 
Week  
18 
o Final Assessment column header was clarified (changes in bold): “Final Assessment and 
Ongoing Treatment / Assessmentsd” 
• 
Section 4.1.2 (Subject Evaluation and Statistics): Updated PP Population to clarify 
evaluation period. (changes in bold): “The Per-Protocol (PP) Population for safety and 
tolerability is defined as all subjects who received at least 75% of the scheduled doses of 
study drugs and RT over the first 2 cycles, as well as, respective safety assessments (up to 
and including the pre-dose assessments scheduled for Cycle 3) without major protocol 
violations over the entire Cohort A concurrent ipilimumab and nivolumab assessment 
period (as defined in Section 3.1.9).” 
• 
Section 5.3.1 (Non-permitted Concomitant Therapies): made corrections to align with 
language in Section 5.1 (Inclusion Criteria) #4 (changes in bold): “Other non-study cancer 
therapy (chemotherapy or immunotherapy), with a wash-out period of 4 weeks (2 weeks 
for chemotherapy, 6 weeks for nitrosoureas and CTLA-4, PD-1, and/or PD-L1 antibodies 
and 12 weeks for other antibodies other than CTLA-4, PD-1, and/or PD-L1 antibodies) prior 
to Day 1.” 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 43 of 70 
Amendment 5 
Issue Date:  12-JUN-2018 
Summary of Changes: 
• 
For subjects who continue nivolumab treatment after Week 18, a dosing option of 480 mg 
every 4 weeks was added.  Rationale: this option was provided based on current dosing 
options that are available. This change was added to the following sections: 
o Synopsis, Section 3.1 (Study Design), and Section 3.1.7 (Treatment Arms and Schema), 
Table 1. “Note: per Amendment 5, nivolumab monotherapy continuing after Week 18 
may be given as 480 mg every 4 weeks starting on Week 20, followed by Weeks 24, 28, 
etc.).” 
• 
Section 3.2 (Flowchart): 
o Footnote c was updated to provide clarification and agreement with Inclusion criterion 
#2 (changes in bold):  “Tumor biopsies are optional but are encouraged. Biopsies are 
prohibited from compromising the requirement for at least one measurable lesion 
undergoing RT and one measurable lesion not undergoing RT.” 
o Footnote d was updated to (1) provide clarification that subjects who have not 
progressed will also have an additional scan at Week 24 and subsequent scans Q12W (± 
7 days) until progression or start of alternate anti-cancer therapy; and (2) to add 
information regarding the 480 mg (every 4 weeks) dosing after Week 18 for nivolumab 
(changes in bold):  
Final Assessment will be 2 weeks (± 3 days) after last study drug, followed by On Study 
Follow-up and Post Study Follow-up. A repeat disease assessment scan is not required at 
the final assessment visit if a scan was done within the previous 6 weeks before the final 
assessment visit. Subjects who do not continue treatment with nivolumab after Week 18 
do not need to have a repeat pregnancy test (if applicable) at the final assessment if the 
subject had this assessment at Week 18.   
For those subjects who are continuing on nivolumab after Week 18 at 240 mg every 2 
weeks ±3 days, Study Visits will continue every 2 weeks ± 3 days during treatment, 
followed by the Final Assessment Visit, On Study Follow-up, and Post Study Follow-up after 
the last nivolumab treatment.  
Per Amendment 5, nivolumab monotherapy continuing after Week 18 may be given as 
480 mg every 4 weeks ±3 days, starting on Week 20, followed by Weeks 24, 28, etc.  
For those subjects who are continuing on nivolumab after Week 18 at 480 mg every 4 
weeks ±3 days, Study Visits will continue every 4 weeks ± 3 days during treatment, 
followed by the Final Assessment Visit, On Study Follow-up, and Post Study Follow-up 
after the last nivolumab treatment. 
Subjects continuing nivolumab monotherapy, and subjects who complete study treatment 
as responders, and subjects who have not progressed (either in irradiated or non-
irradiated tumor burden) will have an additional scan (disease assessments by RECIST 1.1/ 
irRECIST) at Week 24 and subsequent scans Q12W (± 7 days) until progression or start of 
alternate anti-cancer therapy. 
o Footnote e: the following note was added: “For females of child-bearing potential who 
are continuing on nivolumab after Week 18 at 480 mg every 4 weeks, urine pregnancy 
tests may be done every 8 weeks.” 
o Footnote f was updated to provide clarification (changes in bold): “All subjects will 
receive concurrent nivolumab (1 mg/kg) followed by ipilimumab (3 mg/kg) on the same 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 44 of 70 
day every 3 weeks for 4 doses, then followed by nivolumab monotherapy (240 mg 
every 2 weeks ±3 days). See footnote d for ongoing nivolumab monotherapy after 
Week 18. Radiotherapy will be initiated after the first dose and before the second dose 
of immunotherapy. 
o Footnote g was added to reflect current requirements for LDH and thyroid testing; the 
change was added only for ongoing treatment period after Week 18 to allow for the 
core study to have consistent collection of data. 
• 
Section 5.1, Exclusion Criterion # 14 was clarified (changes in bold): “Any condition that, in 
the clinical judgment of the treating physician, is likely to interfere with the interpretability 
of the data or prevent the subject from complying with any aspect of the protocol or that 
may put the subject at unacceptable risk.” 
• 
Section 6.1.2 (Nivolumab Preparation and Administration). “Additional information” was 
added per instructions provided by BMS (added last 2 paragraphs). 
• 
Administrative changes: General spelling, grammar, capitalization, and formatting changes, 
as needed. 
• 
Section 8.7 (Abbreviations) was updated. 
 
 
 
 
 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 45 of 70 
8.2 Participating Study Sites, Investigators and Staff, Laboratories, and 
Sponsor Information 
This information is provided in the Clinical Study File. 
 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 46 of 70 
8.3 Ipilimumab and Nivolumab Dose Delays and Adjustments 
No dose reductions or escalations are permitted. 
Criteria for Dose Delay 
Because of the potential for clinically meaningful immuno-oncology-related AEs requiring early 
recognition and prompt intervention, management algorithms have been developed for the 
following suspected AEs: diarrhea/colitis; elevated creatinine; pneumonitis; elevated liver 
function tests (LFTs); elevated TSH; rash; and neurological AEs (see Section 8.3.1). 
Dose delay criteria apply to all drug-related AEs (regardless of whether or not an event is 
attributed to nivolumab, ipilimumab, or both). All study drugs must be delayed until criteria for 
resumption of treatment are met. 
Nivolumab and ipilimumab administration should be delayed for the following: 
• 
Any Grade ≥ 2 non-skin, drug-related AE, with the following exceptions: 
o 
Grade 2 drug-related fatigue or laboratory abnormalities do not require a treatment 
delay. 
• 
Any Grade 3 skin, drug-related AE. 
• 
Any Grade 3 drug-related laboratory abnormality, with the following exceptions for 
asymptomatic amylase or lipase, AST, ALT, or total bilirubin: 
o 
Grade 3 amylase or lipase abnormalities that are not associated with symptoms or 
clinical manifestations of pancreatitis do not require a dose delay. It is recommended to 
consult with the Sponsor for Grade 3 amylase or lipase abnormalities. 
o 
If a subject has a baseline AST, ALT, or total bilirubin that is within normal limits, delay 
dosing for drug-related Grade ≥ 2 toxicity. 
o 
If a subject has baseline AST, ALT, or total bilirubin within the Grade 1 toxicity range, 
delay dosing for drug-related Grade ≥ 3 toxicity. 
• 
Any AE, laboratory abnormality, or intercurrent illness that, in the judgment of the 
investigator, warrants delaying the dose of study medication. 
Criteria to Resume Treatment 
Subjects may resume treatment with study drugs when the drug-related AE(s) resolve to 
Grade ≤ 1 or baseline value, with the following exceptions: 
• 
Subjects may resume treatment in the presence of Grade 2 fatigue. 
• 
Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in 
the presence of Grade 2 skin toxicity. 
• 
Subjects with baseline Grade 1 AST/ALT or total bilirubin who require dose delays for 
reasons other than a 2-grade shift in AST/ALT or total bilirubin may resume treatment in the 
presence of Grade 2 AST/ALT OR total bilirubin. 
• 
Subjects with combined Grade 2 AST/ALT AND total bilirubin values meeting discontinuation 
parameters should have treatment permanently discontinued. 
• 
Drug-related pulmonary toxicity, diarrhea, or colitis must have resolved to baseline before 
treatment is resumed. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 47 of 70 
• 
Drug-related endocrinopathies adequately controlled with only physiologic hormone 
replacement may resume treatment. 
If the criteria to resume treatment are met, the subject should restart treatment at the next 
scheduled time point per protocol. However, if the treatment is delayed past the next scheduled 
time point per protocol, the next scheduled time point will be delayed until dosing resumes. 
Doses may not be skipped.  For ipilimumab, the intent is to administer all 4 doses if possible.  
If treatment is delayed for > 6 weeks, the subject must be permanently discontinued from study 
therapy, except as specified in the discontinuation criteria. 
Discontinuation Criteria 
Treatment should be permanently discontinued for the following: 
• 
Any Grade 2 drug-related uveitis or eye pain or blurred vision that does not respond to 
topical therapy and does not improve to Grade 1 severity within the re-treatment period OR 
requires systemic treatment. 
• 
Any Grade 3 non-skin, drug-related AE lasting > 7 days, with the following exceptions for 
drug-related laboratory abnormalities, uveitis, pneumonitis, bronchospasm, diarrhea, colitis, 
neurologic AE, hypersensitivity reactions, and infusion reactions: 
o 
Grade 3 drug-related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, neurologic 
adverse event, hypersensitivity reaction, or infusion reaction of any duration requires 
discontinuation. 
o 
Grade 3 drug-related laboratory abnormalities do not require treatment discontinuation 
except those noted below: 
 
Grade 3 drug-related thrombocytopenia > 7 days or associated with bleeding 
requires discontinuation. 
 
Any drug-related LFT abnormality that meets the following criteria requires 
discontinuation: 
 AST or ALT > 8 x ULN. 
 Total bilirubin > 5 x ULN. 
 Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN. 
• 
Any Grade 4 drug-related AE or laboratory abnormality, except for the following events 
which do not require discontinuation: 
o 
Isolated Grade 4 amylase or lipase abnormalities that are not associated with symptoms 
or clinical manifestations of pancreatitis.  
o 
Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with 
clinical sequelae and are corrected with supplementation/appropriate management 
within 72 hours of their onset. 
• 
Any dosing interruption lasting > 6 weeks with the following exceptions: 
o 
Dosing interruptions to allow for prolonged steroid tapers to manage drug-related AEs 
are allowed. Prior to re-initiating treatment in a subject with a dosing interruption 
lasting > 6 weeks, the Investigator must be consulted. Tumor assessments should 
continue as per protocol even if dosing is interrupted. 
o 
Dosing interruptions > 6 weeks that occur for non-drug-related reasons may be allowed 
if approved by the Investigator. Prior to re-initiating treatment in a subject with a dosing 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 48 of 70 
interruption lasting > 6 weeks, the Investigator must be consulted. Tumor assessments 
should continue as per protocol even if dosing is interrupted. 
• 
Any AE, laboratory abnormality, or intercurrent illness that, in the judgment of the 
Investigator, presents a substantial clinical risk to the subject with continued nivolumab or 
ipilimumab dosing. 
Treatment of Nivolumab- or Ipilimumab-related Infusion Reactions 
Since nivolumab and ipilimumab contain only human immunoglobulin protein sequences, it is 
unlikely to be immunogenic and induce infusion or hypersensitivity reactions. However, if such a 
reaction were to occur, it might manifest with fever, chills, rigors, headache, rash, pruritus, 
arthralgia, hypo- or hypertension, bronchospasm, or other symptoms. 
All Grade 3 or 4 infusion reactions should be reported as an SAE if criteria are met. Infusion 
reactions should be graded according to NCI CTCAE, Version 4.03 guidelines. 
Treatment recommendations are provided below and may be modified based on local 
treatment standards and guidelines as appropriate: 
For Grade 1 symptoms: (Mild reaction; infusion interruption not indicated; intervention not 
indicated) 
Remain at bedside and monitor subject until recovery from symptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg (or 
equivalent) and/or paracetamol (acetaminophen) 325 to 1000 mg at least 30 minutes before 
additional nivolumab/ipilimumab administrations. 
For Grade 2 symptoms: (Moderate reaction; requires therapy or infusion interruption but 
responds promptly to symptomatic treatment [e.g., antihistamines, non-steroidal 
anti-inflammatory drugs, narcotics, corticosteroids, bronchodilators, IV fluids]; prophylactic 
medications indicated for 24 hours). 
Stop the nivolumab or ipilimumab infusion, begin an IV infusion of normal saline, and treat the 
subject with diphenhydramine 50 mg IV (or equivalent) and/or paracetamol (acetaminophen) 
325 to 1000 mg; remain at bedside and monitor subject until resolution of symptoms. 
Corticosteroid or bronchodilator therapy may also be administered as appropriate. If the 
infusion is interrupted, restart the infusion at 50% of the original infusion rate when symptoms 
resolve; if no further complications ensue after 30 minutes, the rate may be increased to 100% 
of the original infusion rate. Monitor subject closely. If symptoms recur then no further 
nivolumab or ipilimumab will be administered at that visit. Administer diphenhydramine 50 mg 
IV, and remain at bedside and monitor the subject until resolution of symptoms. The amount of 
study drug infused must be recorded on the eCRF. The following prophylactic premedications 
are recommended for future infusions: diphenhydramine 50 mg (or equivalent) and/or 
paracetamol (acetaminophen) 325 to 1000 mg should be administered at least 30 minutes 
before additional nivolumab or ipilimumab administrations. If necessary, corticosteroids 
(recommended dose: up to 25 mg of IV hydrocortisone or equivalent) may be used. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 49 of 70 
For Grade 3 or Grade 4 symptoms: (Grade 3 [severe reaction; prolonged (i.e., not rapidly 
responsive to symptomatic medication and/or brief interruption of infusion); recurrence of 
symptoms following initial improvement; hospitalization indicated for other clinical sequelae 
(e.g., renal impairment, pulmonary infiltrates). Grade 4 [life-threatening reactions; pressor or 
ventilatory support indicated]). 
Immediately discontinue infusion of nivolumab or ipilimumab. Begin an IV infusion of normal 
saline, and treat the subject as follows. Recommend bronchodilators, epinephrine 0.2 to 1 mg of 
a 1:1,000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 50 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Subject should be monitored until the 
investigator is comfortable that the symptoms will not recur. Nivolumab or ipilimumab will be 
permanently discontinued. Investigators should follow their institutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor subject until recovery from 
symptoms. In the case of late-occurring hypersensitivity symptoms (e.g., appearance of a 
localized or generalized pruritus within 1 week after treatment), symptomatic treatment may be 
given (e.g., oral antihistamine or corticosteroids). 
For subjects who are expected to require more than 4 weeks of corticosteroids or other 
immunosuppressants to manage AEs, the following recommendations should be considered. 
• 
Administer antimicrobial/antifungal prophylaxis per institutional guidelines to prevent 
opportunistic infections such as Pneumocystis jiroveci and fungal infections. 
• 
Early consultation with an infectious disease specialist should be considered. Depending on 
the presentation, consultation with a pulmonologist for bronchoscopy or a 
gastroenterologist for endoscopy may also be appropriate. 
• 
In subjects who develop recurrent AEs in the setting of ongoing or prior immunosuppressant 
use, an opportunistic infection should be considered in the differential diagnosis. 
8.3.1 Management Algorithms for Adverse Events Associated with 
Immuno-oncology Agents 
Please refer to the most current version of the nivolumab IB for current recommendations for 
management of a specific Adverse Event of interest.  The following management algorithms are 
available in the Appendix of the IB: 
• 
GI AE Management 
• 
Renal AE Management 
• 
Pulmonary AE Management 
• 
Hepatic AE Management 
• 
Endocrinopathy Management 
• 
Skin AE Management 
• 
Neurological AE Management 
 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 50 of 70 
8.4 RECIST 1.1 and irRECIST Guidelines  
The Response Evaluation Criteria in Solid Tumors (RECIST) guidelines were revised in 2009 as 
RECIST 1.1.(47) These guidelines have been the widely accepted criteria to assess response and 
progression in solid tumors; however, limitations have been noted in the use of RECIST 1.1 for 
immunotherapy trials. With immunotherapeutic agents, clinical trials have shown that complete 
response, partial response, or stable disease status can still be achieved after an initial increase 
in overall tumor burden, and regression of initial lesions may occur despite development of new 
lesions. The Immune-related Response Criteria (irRC) were developed to address the need for 
response criteria in an immunotherapy setting.(13)  The main difference with irRC was that it 
considered the subject's total tumor burden at each subsequent assessment and required 
confirmation of suspected disease progression with subsequent imaging, approximately four 
weeks later.  In addition, a greater number of lesions (10 vs. 5) were measured in a 
bidimensional manner instead of unidimensionally as in RECIST 1.1.  In 2013, Nishino et al. 
demonstrated that immune-related response criteria using unidimensional measurements were 
highly concordant with the bidimensional results of irRC, but with less measurement 
variability.(48)  Based on these findings and in order to utilize both the established criteria of 
irRC and RECIST 1.1, the two systems have been adapted, modified, and combined into the 
Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).(49)  The adapted 
irRECIST criteria are modifications to the irRC, incorporating the findings of Nishino et al. and the 
advantages of RECIST 1.1 while overcoming the shortcomings of each of the other guidelines.  
The guidelines for RECIST 1.1 are summarized below, followed by a summary for irRECIST. 
RECIST 1.1 
The following section outlines the RECIST 1.1 guidelines as published (47) and as summarized by 
National Cancer Institute for CTEP-involved clinical trials.   
I. 
Disease Parameters for RECIST 1.1 
Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the 
shortest diameter in the case of malignant lymph nodes are used in the RECIST 1.1 criteria. 
Measurable disease.  Measurable lesions are defined as those that can be accurately measured 
in at least one dimension (longest diameter to be recorded) as >20 mm by chest x-ray, as >10 
mm with CT scan, or >10 mm with calipers by clinical exam.  All tumor measurements must be 
recorded in millimeters (or decimal fractions of centimeters). 
Note:  Tumor lesions that are situated in a previously irradiated area might or might not be 
considered measurable.  If the investigator thinks it appropriate to include them, the conditions 
under which such lesions should be considered must be defined in the protocol. 
NOTE for irRECIST: During target lesion selection the radiologist will consider information on 
the anatomical sites of previous intervention (e.g. previous irradiation, RF-ablation, TACE, 
surgery, etc.). Lesions undergoing prior intervention will not be selected as target lesions 
unless there has been a demonstration of progress in the lesion. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 51 of 70 
Malignant lymph nodes.  To be considered pathologically enlarged and measurable, a lymph 
node must be >15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm).  At baseline and in follow-up, only the short axis 
will be measured and followed. 
Non-measurable disease.  All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with ≥ 10 to <15 mm short axis), are considered 
non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses 
(not followed by CT or MRI), are considered as non-measurable. 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not 
be considered as malignant lesions (neither measurable nor non-measurable) since they are, by 
definition, simple cysts.  ‘Cystic lesions’ thought to represent cystic metastases can be 
considered as measurable lesions, if they meet the definition of measurability described above. 
However, if non-cystic lesions are present in the same patient, these are preferred for selection 
as target lesions. 
NOTE for irRECIST:  
Lesions that are partially cystic or necrotic can be selected as target lesions. The longest 
diameter of such a lesion will be added to the Total Measured Tumor Burden (TMTB) of all 
target lesions at baseline. If other lesions with a non-liquid/non-necrotic component are 
present, those should be preferred. 
Brain lesions detected on brain scans can be considered as both target or non-target lesions 
depending on the protocol definition. 
Target lesions.  All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions and recorded 
and measured at baseline.  Target lesions should be selected on the basis of their size (lesions 
with the longest diameter), be representative of all involved organs, but in addition should be 
those that lend themselves to reproducible repeated measurements.  It may be the case that, 
on occasion, the largest lesion does not lend itself to reproducible measurement in which 
circumstance the next largest lesion which can be measured reproducibly should be selected.  A 
sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be 
included in the sum, then only the short axis is added into the sum.  The baseline sum diameters 
will be used as reference to further characterize any objective tumor regression in the 
measurable dimension of the disease. 
Non-target lesions.  All other lesions (or sites of disease) including any non-measureable as well 
as measurable lesions over and above the 5 target lesions should be identified as non-target 
lesions and should also be recorded at baseline.  Measurements of these lesions are not 
required, but the presence, absence, or in rare cases unequivocal progression of each should be 
noted throughout follow-up.  

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 52 of 70 
II. 
Methods for Evaluation of Measurable Disease 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All 
baseline evaluations should be performed as closely as possible to the beginning of treatment 
and never more than 4 weeks before the beginning of the treatment. 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is 
preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam. 
Clinical lesions:  Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥10 mm diameter as assessed using calipers 
(e.g., skin nodules).  In the case of skin lesions, documentation by color photography, including a 
ruler to estimate the size of the lesion, is recommended.  
Chest x-ray:  Lesions on chest x-ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by aerated lung.  However, CT is preferable.  
Conventional CT and MRI:  This guideline has defined measurability of lesions on CT scan based 
on the assumption that CT slice thickness is 5 mm or less.  If CT scans have slice thickness 
greater than 5 mm, the minimum size for a measurable lesion should be twice the slice 
thickness.  MRI is also acceptable in certain situations (e.g. for body scans).   
Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI, which greatly 
impact image quality, lesion conspicuity, and measurement.  Furthermore, the availability of 
MRI is variable globally.  As with CT, if an MRI is performed, the technical specifications of the 
scanning sequences used should be optimized for the evaluation of the type and site of disease.  
Furthermore, as with CT, the modality used at follow-up should be the same as was used at 
baseline and the lesions should be measured/assessed on the same pulse sequence.  It is 
beyond the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters 
for all scanners, body parts, and diseases.  Ideally, the same type of scanner should be used and 
the image acquisition protocol should be followed as closely as possible to prior scans.  Body 
scans should be performed with breath-hold scanning techniques, if possible. 
PET-CT:  At present, the low dose or attenuation correction CT portion of a combined PET-CT is 
not always of optimal diagnostic CT quality for use with RECIST measurements.  However, if the 
site can document that the CT performed as part of a PET-CT is of identical diagnostic quality to 
a diagnostic CT (with IV and oral contrast), then the CT portion of the PET-CT can be used for 
RECIST measurements and can be used interchangeably with conventional CT in accurately 
measuring cancer lesions over time.  Note, however, that the PET portion of the CT introduces 
additional data which may bias an investigator if it is not routinely or serially performed.   
Ultrasound:  Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement.  Ultrasound examinations cannot be reproduced in their entirety for 
independent review at a later date and, because they are operator dependent, it cannot be 
guaranteed that the same technique and measurements will be taken from one assessment to 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 53 of 70 
the next.  If new lesions are identified by ultrasound in the course of the study, confirmation by 
CT or MRI is advised.  If there is concern about radiation exposure at CT, MRI may be used 
instead of CT in selected instances. 
Endoscopy, Laparoscopy:  The utilization of these techniques for objective tumor evaluation is 
not advised.  However, such techniques may be useful to confirm complete pathological 
response when biopsies are obtained or to determine relapse in trials where recurrence 
following complete response (CR) or surgical resection is an endpoint. 
Tumor markers:  Tumor markers alone cannot be used to assess response.  If markers are 
initially above the upper normal limit, they must normalize for a patient to be considered in 
complete clinical response.  Specific guidelines for both CA-125 response (in recurrent ovarian 
cancer) and PSA response (in recurrent prostate cancer) have been published.(50-52)  In 
addition, the Gynecologic Cancer Intergroup has developed CA-125 progression criteria which 
are to be integrated with objective tumor assessment for use in first-line trials in ovarian 
cancer.(53)  
Cytology, Histology:  These techniques can be used to differentiate between partial responses 
(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor types, such as 
germ cell tumors, where known residual benign tumors can remain). 
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens 
during treatment when the measurable tumor has met criteria for response or stable disease is 
mandatory to differentiate between response or stable disease (an effusion may be a side effect 
of the treatment) and progressive disease. 
FDG-PET:  While FDG-PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease).  New lesions on the basis of 
FDG-PET imaging can be identified according to the following algorithm:  
a) Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD based 
on a new lesion. 
b) No FDG-PET at baseline and a positive FDG-PET at follow-up:  If the positive FDG-PET at 
follow-up corresponds to a new site of disease confirmed by CT, this is PD.  If the 
positive FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional 
follow-up CT scans are needed to determine if there is truly progression occurring at 
that site (if so, the date of PD will be the date of the initial abnormal FDG-PET scan).  If 
the positive FDG-PET at follow-up corresponds to a pre-existing site of disease on CT 
that is not progressing on the basis of the anatomic images, this is not PD. 
c) FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy in 
cases where a residual radiographic abnormality is thought to represent fibrosis or 
scarring.  The use of FDG-PET in this circumstance should be prospectively described in 
the protocol and supported by disease-specific medical literature for the indication.  
However, it must be acknowledged that both approaches may lead to false positive CR 
due to limitations of FDG-PET and biopsy resolution/sensitivity. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 54 of 70 
Note:  A ‘positive’ FDG-PET scan lesion means one which is FDG avid with an uptake greater than 
twice that of the surrounding tissue on the attenuation corrected image. 
III. 
Response Criteria for RECIST 1.1 
A. Evaluation of Target Lesions 
Complete Response (CR):  Disappearance of all target lesions.  Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to <10 mm.   
Partial Response (PR):  At least a 30% decrease in the sum of the diameters of target lesions, 
taking as reference the baseline sum diameters 
Progressive Disease (PD):  At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must also demonstrate 
an absolute increase of at least 5 mm.  (Note:  the appearance of one or more new lesions is 
also considered progressions). 
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study 
B. Evaluation of Non-Target Lesions 
Complete Response (CR):  Disappearance of all non-target lesions and normalization of tumor 
marker level.  All lymph nodes must be non-pathological in size (<10 mm short axis) 
Note:  If tumor markers are initially above the upper normal limit, they must normalize for a 
patient to be considered in complete clinical response. 
Non-CR/Non-PD:  Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits 
Progressive Disease (PD):  Appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions.  Unequivocal progression should not normally trump 
target lesion status.  It must be representative of overall disease status change, not a single 
lesion increase.   
Although a clear progression of “non-target” lesions only is exceptional, the opinion of the 
treating physician should prevail in such circumstances, and the progression status should be 
confirmed at a later time by the review panel (or Principal Investigator). 
C. Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started).  The patient's best response assignment 
will depend on the achievement of both measurement and confirmation criteria. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 55 of 70 
1. For Patients with Measurable Disease (i.e., Target Disease) 
Target 
Lesions 
Non-Target Lesions 
New 
Lesions 
Overall 
Response 
Best Overall Response when 
Confirmation is Required* 
CR 
CR 
No 
CR 
>4 wks. Confirmation** 
CR 
Non-CR/Non-PD 
No 
PR 
>4 wks. Confirmation** 
CR 
Not evaluated 
No 
PR 
PR 
Non-CR/Non-PD/not evaluated 
No 
PR 
SD 
Non-CR/Non-PD/not evaluated 
No 
SD 
documented at least once >4 
wks. from baseline** 
PD 
Any 
Yes or No 
PD 
no prior SD, PR or CR 
Any 
PD*** 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
*      See RECIST 1.1 manuscript for further details on what is evidence of a new lesion. 
**    Only for non-randomized trials with response as primary endpoint. 
***  In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease 
progression. 
Note: 
Patients with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be reported as “symptomatic 
deterioration.”  Every effort should be made to document the objective progression even after 
discontinuation of treatment. 
 
2. For Patients with Non-Measurable Disease (i.e., Non-Target Disease) 
Non-Target Lesions 
New Lesions 
Overall Response 
CR 
No 
CR 
Non-CR/non-PD 
No 
Non-CR/non-PD* 
Not all evaluated 
No 
not evaluated 
Unequivocal PD 
Yes or No 
PD 
Any 
Yes 
PD 
* ‘Non-CR/non-PD’ is preferred over ‘stable disease’ for non-target disease since SD is increasingly used as an end-
point for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not 
advised. 
 
D. Duration of Response 
Duration of overall response:  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that progressive disease is objectively documented. 
Duration of stable disease:  Stable disease is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since 
the treatment started, including the baseline measurements.  
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 56 of 70 
irRECIST 
Immune-related RECIST (irRECIST) guidelines according to Bohnsack et al. (49) are presented 
below. 
I. 
Baseline Assessments in irRECIST 
In irRECIST, baseline assessment and measurement of measurable/non-measurable and 
target/non-target lesions and lymph nodes are in line with RECIST 1.1.  One new definition is 
added: If a subject has no measurable and no non-measurable disease at baseline the radiologist 
will assign ‘No Disease’ (irND) as the overall tumor assessment for any available follow-up time 
points unless new measurable lesions are identified and contribute to the total measured tumor 
burden (TMTB).  irND is a valid assessment in studies with adjuvant setting where the protocol 
and study design allow the inclusion of subjects with no visible disease 
II 
Follow-up Assessments in irRECIST 
A. Follow-up recording of target and new measurable lesions 
A key difference in irRECIST is that the appearance new lesions does not automatically 
indicate progression.  Instead, all measured lesions (baseline-selected target lesions and new 
measurable lesions) are combined into the total measured tumor burden (TMTB) at follow up.  
Baseline-selected target lesions and new measurable lesions are NOT assessed separately. 
Measurements of those lesions are combined into the TMTB, and one combined assessment 
provided. 
In order to be selected as new measurable lesions (≤ 2 lesions per organ, ≤ 5 lesions total, per 
time point), new lesions must meet criteria as defined for baseline target lesion selection and 
meet the same minimum size requirements of 10 mm in long diameter and minimum 15 mm in 
short axis for new measurable lymph nodes. New measurable lesions should be prioritized 
according to size, and the largest lesions elected as new measured lesions.  
B. Follow-up non-target assessment 
RECIST 1.1 definitions for assessment of non-target lesions apply.  The response of non-target 
lesions primarily contributes to the overall response assessments of irCR and irNon-CR/Non-PD 
(irNN). Non-target lesions do not affect irPR and irSD assessments. Only a massive and 
unequivocal worsening of non-target lesions alone, even without progress in the TMTB is 
indicative of irPD.  In alignment with RECIST 1.1, baseline selected non-target lesions can never 
convert to measurable lesions, not even if they increase in size at subsequent time points and 
become measurable. Only true new lesions can be measured and contribute to the TMTB. 
C. Follow-up for New Non-Measurable Lesions  
All new lesions not selected as new measurable lesions are considered new non-measurable 
lesions and are followed qualitatively. Only a massive and unequivocal progression of new non-
measurable lesions leads to an overall assessment of irPD for the time point. Persisting new 
non-measurable lesions prevent irCR.  

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 57 of 70 
III 
Overall Assessments for irRECIST 
The irRECIST overall tumor assessment is based on TMTB of measured target and new lesions, 
non-target lesion assessment and new non-measurable lesions. 
At baseline, the sum of the longest diameters (SumD) of all target lesions (up to 2 lesions per 
organ, up to total 5 lesions) is measured.  At each subsequent tumor assessment (TA), the SumD 
of the target lesions and of new, measurable lesions (up to 2 new lesions per organ, total 5 new 
lesions) are added together to provide the total measurable tumor burden (TMTB). 
Overall Assessments by irRECIST 
Complete Response 
(irCR) 
Complete disappearance of all measurable and non-measurable lesions. Lymph 
nodes must decrease to < 10 mm in short axis. 
Partial Response 
(irPR) 
Decrease of ≥ 30% in TMTB relative to baseline, non-target lesions are irNN, and 
no unequivocal progression of new non-measurable lesions 
• 
If new measurable lesions appear in subjects with no target lesions at 
baseline, irPD will be assessed. That irPD time point will be considered a new 
baseline, and all subsequent time points will be compared to it for response 
assessment. irPR is possible if the TMTB of new measurable lesions decreases 
by ≥ 30% compared to the first irPD documentation 
• 
irRECIST can be used in the adjuvant setting, in subjects with no visible 
disease on CT/MRI scans. The appearance of new measurable lesion(s) 
automatically leads to an increase in TMTB by 100% and leads to irPD. These 
subjects can achieve a response if the TMTB decreases at follow-up, as a sign 
of delayed response. 
• 
Based on the above, sponsors may consider enrolling subjects with no 
measurable disease and/or no visible disease in studies with response related 
endpoints. 
Stable Disease 
(irSD) 
Failure to meet criteria for irCR or irPR in the absence of irPD 
Progressive Disease 
(irPD) 
Minimum 20% increase and minimum 5 mm absolute increase in TMTB compared 
to nadir, or irPD for non-target or new non-measurable lesions. Confirmation of 
progression is recommended minimum 4 weeks after the first irPD assessment. An 
irPD confirmation scan may be recommended for subjects with a minimal TMTB 
%-increase over 20% and especially during the flare time-window of the first 12 
weeks of treatment, depending on the compound efficacy expectations, to 
account for expected delayed response. 
• 
In irRECIST a substantial and unequivocal increase of non-target lesions is 
indicative of progression. 
• 
IrPD may be assigned for a subject with multiple new non-measurable lesions 
if they are considered to be a sign of unequivocal massive worsening 
Other 
irNE: used in exceptional cases where insufficient data exist.  
irND: in adjuvant setting when no disease is detected 
irNN: no target disease was identified at baseline, and at follow-up the subject 
fails to meet criteria for irCR or irPD 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 58 of 70 
8.5 Recommended Guidelines for Radiation Therapy 
8.5.1 Target selection for radiation therapy 
The target for radiation therapy will be selected at the discretion of the protocol investigators.   
The target should not have been previously irradiated.   
In subjects that have had prior radiotherapy, treatment should not be carried out if the target is 
within 3 cm of the organ below (and criteria in parentheses are met): 
Lung (prior v20 ≥25%) 
Spinal cord (prior dose >40 Gy within 3 cm of target) 
Brain, Globe, Optic nerves, Brainstem (prior dose >50 Gy within 3 cm of target) 
Brachial plexus (prior dose >50 Gy within 3 cm of target) 
Bowel and stomach (prior dose >40 Gy within 3 cm of target) 
 
The target should be one that is not exclusively within bone (i.e., a bone metastasis with no 
extraosseous soft tissue component), and therefore cannot be assessed for radiographic 
response by protocol-defined criteria.   
Priority should be given to irradiating symptomatic metastases.   
If multiple symptomatic targets are present, the largest target that can safely be irradiated 
should be chosen.   
More than one target can be irradiated, but at least one site of measurable disease must be not 
be irradiated for response assessment purposes (see protocol). 
The radiotherapy target should be described categorically as one of the following: 
Lymph node 
Bone 
Skin 
Lung 
Liver  
Gastrointestinal tract 
Muscle 
Other 
 
The target for radiation therapy should be anatomically described (including laterality) in order 
to aid in radiographic response determination by the reference radiologist. 
 
8.5.2 Treatment position, immobilization, and simulation 
The treatment position will be comfortable enough to allow the patient to complete treatment, 
and will be chosen to preserve organ at risk constraints and provide adequate planning target 
volume coverage. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 59 of 70 
Immobilization devices will be used to enhance reproducibility of setup. 
CT simulation will be carried out for all radiation therapy targets.   
The CT simulation should take place with the treatment position, with immobilization devices in 
place. 
The CT scan should include the entire treatment target, and 15 cm of the body superior and 
inferior to this.  This will ensure the entire anatomic structure will be included in the planning CT 
image for proper evaluation of the normal tissue dose-volume histogram, which is used as 
treatment planning criteria. 
For targets within 5 cm of: 
Must be included in simulation CT scan: 
Either lung 
Thoracic inlet through 5 cm below the 
diaphragm/lung parenchyma 
Either kidney 
Entire volume of bilateral kidney parenchyma 
Liver 
Entire volume of liver 
Colon or rectum 
Entire abdomen and pelvis (diaphragm dome 
through ischial tuberosities) 
 
The CT scan slice thickness should be no more than 3 mm.  
The use of motion assessment and compensation techniques (including, but not limited to 4D 
CT, slow CT, breath-hold techniques, compression-belt, and respiratory gating) are permitted for 
moving targets, but not required. 
The use of contrast media for the CT scan is permitted, but not required. 
The use of adjunct imaging for simulation (PET, MRI) is permitted, but not required. 
8.5.3 Target delineation 
Target delineation will be carried out according to International Commission on Radiation Units 
(ICRU) guidelines 50 and 62. 
The gross tumor volume (GTV) is defined as the clinically and/or radiographically apparent site 
of melanoma chosen as a radiation therapy target.   
The clinical target volume (CTV) will be the same as the GTV. 
The internal target volume (ITV) will be determined based on motion assessment and 
compensation strategies applied (if any).  If no motion assessment is undertaken, then ITV will 
be the same as the CTV. 
The planning target volume (PTV) will be determined based on the anticipated setup 
uncertainty, machine tolerance, and intratreatment variation in CTV and/or ITV.  This is required 
to be between 2 and 10 mm and need not be isotropic.   

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 60 of 70 
8.5.4 Organ at risk dose (OAR) delineation and dose constraints 
The following OARs should be delineated on the CT simulation scan when they are within 10 cm 
of the PTV:   
Organ at risk (OAR) 
Definition 
Skin 
Volume within 5 mm below skin surface or “outer” contour 
Brain (not brainstem) 
 
Lens, left 
 
Lens, right 
 
Globe, left 
Globe, right 
 
Optic nerve, left 
 
Optic nerve, right 
 
Optic chiasm 
 
Brainstem (not medulla) 
 
Cochlea, left  
http://www.ncbi.nlm.nih.gov/pubmed/15803007 
Cochlea, right 
http://www.ncbi.nlm.nih.gov/pubmed/15803007 
Medulla and spinal cord 
Bone limits of spinal canal until L2 
Spinal cord subvolume 
http://www.ncbi.nlm.nih.gov/pubmed/23864755 
Larynx 
http://www.ncbi.nlm.nih.gov/pubmed/24673866 
Esophagus 
http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361 
Brachial plexus, left 
http://www.ncbi.nlm.nih.gov/pubmed/18448267 
Brachial plexus, right 
http://www.ncbi.nlm.nih.gov/pubmed/18448267 
Ribs, left 
http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361 
Ribs, right 
http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361 
Trachea and mainstem bronchi 
http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361 
*Lung, left 
http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361 
*Lung, right 
http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361 
Bronchioles 
http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361 
Great vessels 
http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361 
Pericardium/Heart 
http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361 
Stomach 
http://www.ncbi.nlm.nih.gov/pubmed/24890348 
*Liver 
http://www.ncbi.nlm.nih.gov/pubmed/24890348 
Common bile duct 
http://www.ncbi.nlm.nih.gov/pubmed/24890348 
*Renal cortex, left 
 
*Renal cortex, right 
 
Renal hilum, left 
 
Renal hilum, right 
 
Ureter, left 
 
Ureter, right 
 
*Colon 
http://www.ncbi.nlm.nih.gov/pubmed/24890348 
Duodenum 
http://www.ncbi.nlm.nih.gov/pubmed/24890348 
Jejunum 
http://www.ncbi.nlm.nih.gov/pubmed/24890348 
Ileum 
http://www.ncbi.nlm.nih.gov/pubmed/24890348 
Cauda equine 
Bone limits of spinal canal below L2 
Lumbrosacral plexus, left 
http://www.ncbi.nlm.nih.gov/pubmed/22342301 
Lumbrosacral plexus, right 
http://www.ncbi.nlm.nih.gov/pubmed/22342301 
*Rectum 
http://www.ncbi.nlm.nih.gov/pubmed/22483697 
Bladder wall 
http://www.ncbi.nlm.nih.gov/pubmed/22483697 
Penile bulb 
http://www.ncbi.nlm.nih.gov/pubmed/22483697 
Femoral head, left 
http://www.ncbi.nlm.nih.gov/pubmed/22483697 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 61 of 70 
Organ at risk (OAR) 
Definition 
Femoral head, right 
http://www.ncbi.nlm.nih.gov/pubmed/22483697 
*Both lungs, both kidneys, the liver, colon and rectum must be delineated in their entirety when included in the CT 
simulation scan.   
 
 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 62 of 70 
OARs should be constrained so that a dose of 27 Gy can be delivered in 3 fractions without 
exceeding limits below.   
OAR 
Volume 
Volume Max Dose 
Max Point Dose** 
Endpoint (≥Grade 
3) 
Skin 
<10 cc 
30 Gy 
33 Gy 
Ulceration 
Brain 
<0.5 cc 
18 Gy 
23.1 Gy  
Necrosis 
Lens (right or left) 
 
 
12 Gy 
Keratitis 
Globe (right or left) 
 
 
16.2 Gy 
Uveitis 
Optic nerves and chiasm 
(combined) 
<0.2 cc 
15.3 Gy 
17.4 Gy  
Neuritis 
Cochlea (right or left) 
 
 
17.1 Gy  
Hearing loss 
Brainstem (not medulla) 
<0.5 cc 
18 Gy 
23.1 Gy  
Cranial neuropathy 
Medulla and spinal cord 
<0.35 cc 
<1.2 cc 
18 Gy 
12.3 Gy 
21.9 Gy 
Myelitis 
Spinal cord subvolume  
<10% of 
subvolume 
18 Gy 
21.9 Gy 
Myelitis 
Larynx 
 
 
26.4 Gy 
Laryngitis 
Esophagus*  
<5 cc 
17.7 Gy 
25.2 Gy 
Stenosis/fistula 
Brachial plexus (right or 
left) 
<3 cc 
20.4 Gy 
24  Gy 
Neuropathy 
Ribs (each rib) 
<1 cc 
<30 cc 
28.8 Gy 
30 Gy 
36.9 Gy 
Pain or fracture 
Trachea and main bronchi 
(combined)* 
<4 cc 
15 Gy 
30 Gy 
Stenosis/fistula 
Lung (right and left 
combined) 
1500 cc 
11.6 Gy 
 
Basic lung function 
Lung (right and left 
combined) 
1000 cc 
12.4 Gy 
 
Pneumonitis 
Bronchioles  
<0.5 cc 
18.9 Gy 
23.1 Gy 
Stenosis with 
atelectasis 
Great vessels 
<10 cc 
39 Gy 
45 Gy 
Aneurysm 
Pericardium/Heart 
<15 cc 
24 Gy 
30 Gy 
Pericarditis 
Stomach 
<10 cc 
16.5 Gy 
22.2 Gy 
Ulceration/fistula 
Liver 
700 cc 
19.2 Gy 
 
Basic liver function 
Common bile duct 
 
 
36 Gy 
Stenosis 
Renal cortex (right and left 
combined) 
200 cc 
16 Gy 
 
Basic renal function 
Renal hilum (right or left) 
<66% of 
volume 
18.6 Gy 
 
Malignant 
hypertension 
Ureter (right or left) 
 
 
40 Gy 
Stenosis 
Colon* 
<20 cc 
24 Gy 
28.2 Gy 
Colitis/fistula 
Duodenum*  
<5 cc 
<10 cc 
16.5 Gy 
11.4 Gy 
22.2 Gy 
Ulceration 
Jejunum and Ileum 
(combined)* 
<5 cc 
17.7 Gy 
25.2 Gy 
Enteritis/obstruction 
Cauda equine 
<5 cc 
21.9 Gy  
24 Gy 
Neuritis 
Lumbrosacral plexus (right 
or left) 
<5 cc 
22.5 Gy 
24 Gy 
Neuropathy 
Rectum* 
<20 cc 
24 Gy 
28.2 Gy 
Proctitis/fistula 
Bladder wall 
<15 cc 
16.8 Gy 
28.2 Gy 
Cystitis/fistula 
Penile bulb 
<3 cc 
21.9 Gy 
42 Gy 
Impotence 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 63 of 70 
Femoral heads (right or left) 
<10 cc 
21.9 Gy 
42 Gy 
Necrosis 
*avoid circumferential irradiation 
**point defined as 0.035 cc or less 
8.5.5 Beam selection and geometry, planning technique and treatment delivery 
In general, beams should be chosen to preserve OAR constraints and provide adequate PTV 
dosing (D95 ≥95% of the prescription dose), while respecting mechanical constraints of 
equipment.  No minimum number of beams is necessary.   Coplanar and non-coplanar beams 
are permitted. 
Any form of external beam radiotherapy is acceptable (high energy photons, electrons, or 
protons), provided the dose is expressed in cobalt-Gy equivalent (CGyE) or Gy equivalent.  Beam 
energy should be chosen in consideration of penetration depth, neutron contamination, etc.  To 
account for the radiobiologic effectiveness of electrons, investigators are encouraged to 
prescribe the radiation dose to the 90% isodose line that encompasses the PTV.   
Radiotherapy must be planned in 3-dimensions, and dose-volume analyses are required to 
ensure OAR constraints and PTV coverage is adequate.  For 3D conformal planning, both 
physical and dynamic wedges can be used.  Both MLC and block could be used for beam 
confinement when using photons. 
Planning and treatment delivery can be carried out using any technique (non-conformal, 
conformal, intensity-modulated, volume modulated arc, etc) using any mechanism of external 
beam radiation delivery (linear accelerator, CyberKnife™, etc). 
Use of tissue equivalent bolus to ensure adequate build-up is permitted for the treatment of 
superficial targets. 
Verification of accurate subject positioning for treatment must occur through the generation 
and assessment of imaging (MV port films, kV images, cone beam CT, etc) or direct inspection of 
light fields (for electron beam therapy).  Conventional subject setup with skin tattoos or optical 
surface imaging can only be used as initial subject alignment, but not final positioning. 
8.5.6 Radiotherapy timing and dose fractionation 
Treatment will be initiated after the first dose of immunotherapy, but before the second dose of 
immunotherapy. 
Subjects receiving 27 Gy in 3 fractions should be scheduled to receive treatment on non-
consecutive weekdays, no more than 2 days/week, over no more than 14 days.  Ideally, 
treatment will be given with 2 days between treatment (Monday/Thursday/Monday, 
Tuesday/Friday/Tuesday, Monday/Friday/Tuesday, or Tuesday/Friday/Wednesday schedule). 
Subjects receiving 30 Gy in 10 fractions should be scheduled to receive treatment on 
consecutive weekdays, no more than 5 days/week, over no more than 14 days. 
Dose modifications for radiotherapy as a result of toxicity are allowed per the Investigator’s 
assessment. 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 64 of 70 
8.6 Exploratory Assessment of Correlative Immunologic Research 
Peripheral blood and optional tumor samples (when available) will be collected as outlined in 
Section 3.2 and banked for testing at the end of the study.  Separate instructions will be 
provided regarding the processing, storage and testing of these samples.  Testing may include 
but may not be limited to the following: 
• 
lymphocyte phenotype using markers such as ICOS, PD-1, and CD25 
• 
the quantities of myeloid derived suppressor cells (MDSCs), defined as CD14+HLA-DRlow 
cells 
• 
antibody and functional T cell responses to tumor associated antigens (i.e. NY-ESO-1) for 
relevant subjects  
• 
serum cytokine levels such as TNF-alpha, IFN-gamma, IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-12, and TGF-beta 
• 
Serum and plasma microparticle and exosome nanoFACS and proteomic profiles 
• 
T cell repertoire diversity in peripheral blood and tumor. 
Additional investigational methods will be used to characterize and measure components of the 
immune response based upon the latest available technology. 
 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 65 of 70 
8.7 Abbreviations 
AE 
adverse event 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
CRF 
Case report form 
CTCAE 
Common Terminology Criteria for Adverse Events 
CTLA-4 
Cytotoxic T lymphocyte-associated antigen 4  
DCR 
Disease control rate 
DLT 
dose-limiting toxicity 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
Electronic Case Report Form 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GMP 
Good manufacturing practice 
HLA 
Human Leukocyte Antigen 
HNSCC 
Head and neck squamous cell carcinoma 
IB 
Investigator Brochure 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonization 
IL 
interleukin 
IND 
Investigational new drug 
irAE 
Immune-related adverse event 
irRC 
immune-related response criteria 
irRECIST 
Immune-related Response Evaluation Criteria In Solid Tumors 
IV 
intravenous 
IRB 
Institutional Review Board 
LICR 
Ludwig Institute for Cancer Research 
mAb 
Monoclonal antibody 
MDSC 
myeloid derived suppressor cells 
MTD 
maximum tolerated dose 
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse 
Events 
NK 
Natural killer 
OAR 
Organ at risk 
ORR 
Objective Response Rate 
OS 
Overall survival 
PBMC 
Peripheral blood mononuclear cell 
PD-1 
Programmed death-1  
PD-L1 
Programmed death ligand 1 
PFS 
Progression free survival 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 66 of 70 
PK 
Pharmacokinetics 
Q2W 
Every 2 weeks 
Q4W 
Every 4 weeks 
Q6W 
Every 6 weeks 
Q12W 
Every 12 weeks 
RECIST 
Response Evaluation Criteria in Solid Tumors 
RT 
Radiotherapy 
SAE 
Serious Adverse Event 
SD 
Standard Deviation 
TME 
Tumor microenvironment 
TIL 
tumor-infiltrating lymphocyte 
ULN 
Upper limit of normal 
 
 
 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 67 of 70 
9 References 
1. 
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA 
Cancer J Clin. 2011;61(2):69-90. 
2. 
Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III 
multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with 
metastatic melanoma. J Clin Oncol. 1999;17(9):2745-51. 
3. 
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon 
alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative 
Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7-17. 
4. 
Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U, et al. A pooled analysis 
of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for 
melanoma. Clin Cancer Res. 2004;10(5):1670-7. 
5. 
Atkins M, Lotze M, Dutcher J, et al. High-dose recombinant interleukin 2 therapy for 
patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.  J 
Clin Oncol. 1999;17:2105-16. 
6. 
Long G, Stroyakovskiy D, Gogas H, Levchenko E, et al. Dabrafenib and trametinib versus 
dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 
3 randomised controlled trial. Lancet. 2015;Published Online: 30 May 2015. 
7. 
Yervoy™ (ipilimumab) [package insert] injection, for intravenous use. Initial U.S. 
Approval 2011. Bristol-Myers Squibb, Princeton, NJ. Available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf. Accessed 
December 3, 2011. 
8. 
Opdivo® (nivolumab) [package insert] injection, for intravenous use, Initial US Approval 
2014. Bristol-Myers Squibb Company, Princeton, NJ; Available at: 
http://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed March 17, 2015. 
9. 
KEYTRUDA® (pembrolizumab) [package insert] for injection fiu, Initial US Approval 2014. 
Merck and Co, Whitehouse Station, NJ; Available at: 
http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed 
November 3, 2014. 
10. 
Hodi F, O'Day S, McDermott D, et al.  Improved survival with ipilimumab in patients with 
metastatic melanoma. N Engl J Med 2010;363:711-23. 
11. 
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus 
dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-
26. 
12. 
Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 
blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin 
Cancer Res. 2012;18(7):2039-47. 
13. 
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the 
evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin 
Cancer Res. 2009;15(23):7412-20. 
14. 
Weber J, Thompson J, Hamid O, et al.  A randomized, double-blind, placebo-controlled, 
phase II study comparing the tolerability and efficacy of ipilimumab administered with or 
without prophylactic budesonide in patients with unresectable stage III or IV melanoma.  Clin 
Cancer Res 2009;15:5591-8. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 68 of 70 
15. 
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, 
activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 
2012;366(26):2443-54. 
16. 
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. 
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma 
receiving nivolumab. J Clin Oncol. 2014;32(10):1020-30. 
17. 
Robert C, Long G, Brady B, et al. Nivolumab in previously untreated melanoma without 
BRAF mutation.  N Engl J Med. 2015;372:320-30. 
18. 
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab 
plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-33. 
19. 
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. 
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J Med. 
2015;372(21):2006-17. 
20. 
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey L, et al. Combined Nivolumab and 
Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;May 31, 2015. 
21. 
Schild SE. Role of radiation therapy in the treatment of melanoma. Expert Rev 
Anticancer Ther. 2009;9(5):583-6. 
22. 
Johanson CR, Harwood AR, Cummings BJ, Quirt I. 0-7-21 radiotherapy in nodular 
melanoma. Cancer. 1983;51(2):226-32. 
23. 
Huguenin P, Kieser S, Glanzmann C, Capaul R, Lutolf U. Radiotherapy for metastatic 
carcinomas of the kidney or melanomas: an analysis using palliative end points.  Int J Radiat 
Oncol Biol Phys 1998;41:401-5. 
24. 
Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-
dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J 
Radiat Oncol Biol Phys. 1985;11(10):1837-9. 
25. 
Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, et al. Fraction size in 
external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 
1991;20(3):429-32. 
26. 
Olivier K, Schild S, Morris C, Brown P, Markovic S. A higher radiotherapy dose is 
associated with more durable palliation and longer survival in patients with metastatic 
melanoma.  Cancer. 2007;110:1791-5. 
27. 
Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with 
fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1306-10. 
28. 
Dewan M, Galloway A, Kawashima N, et al. Fractionated but not single-dose 
radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 
antibody.  Clin Cancer Res. 2009;15:5379-88. 
29. 
Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative 
radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 
2009;114(3):589-95. 
30. 
Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab 
alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: 
results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24(7):1813-21. 
31. 
Lugade A, Moran J, Gerber S, Rose R, Frelinger J, Lord E. Local radiation therapy of B16 
melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic 
to the tumor. J Immunol. 2005;174:7516-23. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 69 of 70 
32. 
Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. 
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces 
successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259-71. 
33. 
Chakravarty PK, Alfieri A, Thomas EK, Beri V, Tanaka KE, Vikram B, et al. Flt3-ligand 
administration after radiation therapy prolongs survival in a murine model of metastatic lung 
cancer. Cancer Res. 1999;59(24):6028-32. 
34. 
Demaria S, Ng B, Devitt M, et al. Ionizing radiation inhibition of distant untreated tumors 
(abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004;58:862-70. 
35. 
Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune-
mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a 
mouse model of breast cancer. Clin Cancer Res. 2005;11(2 Pt 1):728-34. 
36. 
Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and 
stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat 
Oncol Biol Phys. 2013;86(2):343-9. 
37. 
Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and 
anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 
2014;124(2):687-95. 
38. 
Twyman-Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, et al. Radiation and dual 
checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 
2015;520(7547):373-7. 
39. 
Formenti S, Friedman K, Chao K, et al. Abscopal response in irradiated patients: Results 
of a proof of principle trial.  Int J Radiat Oncol Biol Phys. 2008;72:S6-S7. 
40. 
Seung S, Curti B, Crittenden M, Walker E, Coffey T, et al. Phase 1 study of stereotactic 
body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med. 
2012;4(137):137ra74. 
41. 
Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic 
correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-
31. 
42. 
Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to 
radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer 
Immunol Res. 2013;1(6):365-72. 
43. 
Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated 
with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85(2):293-
5. 
44. 
Sullivan R, Lawrence D, Wargo J, Oh K, Gonzalez R, Piris A. Case records of the 
Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma.  
N Engl J Med 2013;369:173-83. 
45. 
Barker C, Postow MA, Khan S, Beal K, Parhar P, Yamada Y, et al. Concurrent radiotherapy 
and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res. 
2013;1(2):92-8. 
46. 
Martin-Algarra S, Haanen JB, Horak CE, Bhatia S, Ribas A, Hwu WJ, et al. Safety of 
reduced infusion times for nivolumab plus ipilimumab and nivolumab alone in advanced 
melanoma. Eur Soc for Med Onc (ESMO). 2016:Poster 3386. 
47. 
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J 
Cancer. 2009;45(2):228-47. 

 
 
C O N F I D E N T I A L  
SOP-C01-TMP-3 version 3  
LUD2015-006 Protocol Amendment 5 (Final, 12-JUN-2018) 
Page 70 of 70 
48. 
Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya N, Hodi F. Developing a 
common language for tumor response to immunotherapy: immune-related response criteria 
using unidimensional measurements Clin Cancer Res 2013 2013;19(14):3936-43. 
49. 
Bohnsack O, Ludajic K, Hoos A. Adaptation of the immune-related response criteria: 
irRECIST (ESMO 2014 Poster). Annals of Oncology. 2014;25(S4):iv361-iv72. 
50. 
Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: New 
guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer 
Inst. 2004;96(6):487-8. 
51. 
Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility 
and response guidelines for phase II clinical trials in androgen-independent prostate cancer: 
recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 
1999;17(11):3461-7. 
52. 
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and 
end points of clinical trials for patients with progressive prostate cancer and castrate levels of 
testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin 
Oncol. 2008;26(7):1148-59. 
53. 
Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, et al. 
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. 
Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92(18):1534-5.